WO2016124160A1 - 作为egfr抑制剂的嘧啶并嘧啶二酮衍生物及其应用 - Google Patents

作为egfr抑制剂的嘧啶并嘧啶二酮衍生物及其应用 Download PDF

Info

Publication number
WO2016124160A1
WO2016124160A1 PCT/CN2016/073726 CN2016073726W WO2016124160A1 WO 2016124160 A1 WO2016124160 A1 WO 2016124160A1 CN 2016073726 W CN2016073726 W CN 2016073726W WO 2016124160 A1 WO2016124160 A1 WO 2016124160A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
cancer
compound
substituted
alkyl
Prior art date
Application number
PCT/CN2016/073726
Other languages
English (en)
French (fr)
Inventor
李洪林
徐玉芳
谢华
赵振江
郝永佳
王霞
丁健
Original Assignee
华东理工大学
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 华东理工大学 filed Critical 华东理工大学
Priority to CN201680008995.3A priority Critical patent/CN107428763B/zh
Publication of WO2016124160A1 publication Critical patent/WO2016124160A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Definitions

  • the present invention relates to the field of medicinal chemistry; in particular, the present invention relates to novel pyrimidopyrimidinedione derivatives, methods for their synthesis and their use as EGFR inhibitors in the preparation of medicaments for tumor-related diseases.
  • Cancer also known as malignant tumor, is a large class of diseases characterized by abnormal cell proliferation and metastasis. It has the characteristics of high morbidity and high mortality, and is one of the malignant diseases that threaten human health and cause death.
  • Research data shows that there were 12.7 million cancer patients worldwide in 2008, including more than 7 million deaths. In the world, 20% of new cancer patients are in China, and 24% of cancer patients are in China. If no effective measures are taken to prevent it or a better treatment plan, it is estimated that by 2030, there will be 26 million new cancer cases every year worldwide, and the number of cancer deaths will reach 17 million.
  • lung cancer is the most common malignant tumor with morbidity and mortality worldwide, and non-small cell lung cancer (NSCLC) accounts for more than 80% of lung cancer patients.
  • NSCLC non-small cell lung cancer
  • WHO World Health Organization
  • Protein tyrosine kinase is an important factor in the signal transduction process and participates in a series of cellular activities, which are closely related to cell growth, differentiation and proliferation. It catalyzes the transfer of the ⁇ -phosphate group of ATP to the tyrosine residues of many important proteins, phosphorylating the phenolic hydroxyl group, and transmitting signals.
  • EGFR epidermal growth factor receptor tyrosine kinase
  • EGFR is a constitutive expression component of many normal epithelial tissues (such as skin and hair follicles), and in most solid tumors, EGFR is overexpressed or highly expressed. For example, in lung cancer, the expression rate of EGFR reaches 40-80%. Therefore, selectively inhibiting EGFR and interfering with its signal transduction pathway can achieve the purpose of treating lung cancer, and opens up a feasible way for targeted treatment of lung cancer.
  • EGFR targeted drugs such as gefitinib (Iressa), erlotinib (Tarceva) and other first-line drugs have been proved to be very effective in the treatment of lung cancer.
  • EGFR targeted drugs such as gefitinib (Iressa), erlotinib (Tarceva) and other first-line drugs have been proved to be very effective in the treatment of lung cancer.
  • clinical practice has shown that most patients with non-small cell lung cancer develop acquired resistance within 6-12 months after treatment with gefitinib or erlotinib.
  • the resistance of approximately 50% of cases is related to a mutation in one amino acid residue in the EGFR kinase domain (mutation of the 790 threonine residue to methionine, T790M) (The New England Journal of Medicine, 2005, 352, 786-792).
  • the T790M mutation results in steric hindrance when the inhibitor binds to EGFR or increases the affinity of EGFR to ATP, making the anticancer effect of such reversible binding competitive inhibitors greatly diminished.
  • the emergence of drug resistance not only reduces the patient's sensitivity to drugs, but also greatly reduces the quality of life of cancer patients.
  • a series of irreversible ATP competitive inhibitors (such as CI-1033, HKI-272, PF00299804, etc.) have entered the clinical research stage.
  • the irreversible inhibitor contains a Michael acceptor fragment that forms a covalent bond with a conserved amino acid residue (Cys797) of the ATP binding site of EGFR, thereby obtaining a stronger EGFR binding affinity than the reversible inhibitor.
  • Cys797 conserved amino acid residue
  • Another object of the present invention is to provide a pharmaceutical composition comprising the above compound.
  • Still another object of the present invention is to provide use of the above compounds for the preparation of a medicament for treating an EGFR-related disease or inhibiting EGFR.
  • the invention provides a compound of formula I or a pharmaceutically acceptable salt thereof:
  • A is a benzene ring, a five- or six-membered heterocyclic ring, or a C 3 -C 8 cycloalkyl group;
  • R 1 is each independently selected from the group consisting of hydrogen, halogen, C 1 -C 3 alkoxy, C 1 -C 3 alkyl, C 1 -C 4 alkylamido, substituted piperazinyl, substituted homopiperazinyl, Substituted morpholinyl, substituted thiomorpholinyl, 4-N-methylpiperazinyl, 4-N-acetylpiperazinyl, 4-N,N-dimethylpiperidinyl, substituted piperazine a pyridine group, -NR a R b , wherein R a and R b are independently selected from an alkyl group and a nitrogen-containing alkyl group;
  • R 2 is each independently selected from the group consisting of:
  • R 3 is selected from the group consisting of hydrogen, C 1 -C 10 alkyl, substituted C 1 -C 10 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, optionally substituted C 3 a -C 8 cycloalkyl group, an optionally substituted aryl group, an optionally substituted benzyl group, an optionally substituted heterocyclic group, an optionally substituted aromatic heterocyclic group;
  • n is an integer from 0-7.
  • the compound is as shown in Formula II:
  • R 1 , R 2 and R 3 are as defined above;
  • n is an integer from 0 to 5.
  • the compound is as shown in Formula III:
  • R 2 is selected from
  • R 3 is selected from C 1 -C 6 alkyl, preferably methyl or isopropyl; or phenyl substituted C 1 -C 6 alkyl, preferably benzyl; R 4 , R 5 , R 6 , R 7 and R 8 independent from the following group:
  • R 5 and R 8 are H; or, R 5 , R 7 and R 8 are H.
  • the invention provides a compound selected from the group consisting of: or a pharmaceutically acceptable salt thereof:
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising the compound of the first aspect of the invention, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.
  • the pharmaceutical composition is a dosage form suitable for oral administration, including but not limited to tablets, solutions, suspensions, capsules, granules, powders.
  • the invention provides the use of a compound of the first aspect of the invention for the manufacture of a medicament for the treatment or prevention of an EGFR mediated disease, or inhibition of EGFR.
  • the EGFR mediated disease is cancer.
  • the cancer is selected from the group consisting of non-small cell lung cancer, small cell lung cancer, lung adenocarcinoma, lung squamous cell carcinoma, breast cancer, prostate cancer, glioma, ovarian cancer, head and neck Squamous cell carcinoma, cervical cancer, esophageal cancer, liver cancer, kidney cancer, pancreatic cancer, colon cancer, skin cancer, leukemia, lymphoma, gastric cancer, multiple myeloma and solid tumors.
  • the invention provides a method of treating or preventing an EGFR mediated disease using a compound of the first aspect of the invention.
  • the EGFR-mediated disease is cancer; preferably, the cancer is selected from the group consisting of non-small cell lung cancer, small cell lung cancer, lung adenocarcinoma, lung squamous cell carcinoma, breast cancer, prostate cancer , glioma, ovarian cancer, head and neck squamous cell carcinoma, cervical cancer, esophageal cancer, liver cancer, kidney cancer, pancreatic cancer, colon cancer, skin cancer, leukemia, lymphoma, gastric cancer, multiple myeloma and solid tumor .
  • the cancer is selected from the group consisting of non-small cell lung cancer, small cell lung cancer, lung adenocarcinoma, lung squamous cell carcinoma, breast cancer, prostate cancer , glioma, ovarian cancer, head and neck squamous cell carcinoma, cervical cancer, esophageal cancer, liver cancer, kidney cancer, pancreatic cancer, colon cancer, skin cancer, leukemia, lymphoma, gastric cancer, multiple myelo
  • the present inventors synthesized a candidate compound having EGFR inhibitory activity. Structural optimization of the candidate compounds was carried out, and a series of pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione compounds which were not reported in the literature were designed and synthesized. . A series of compounds were tested for activity at the molecular and cellular levels, resulting in a batch of compounds that selectively inhibit the EGFR T790M mutation.
  • alkyl refers to a saturated branched or straight-chain alkyl group having a carbon chain length of from 1 to 10 carbon atoms, and preferred alkyl groups include 2-8, 1-6, 1-4, 3-8 alkyl groups of 1-3 carbon atoms.
  • alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, heptyl, and the like.
  • the alkyl group may be substituted by one or more substituents, for example by halogen or haloalkyl.
  • the alkyl group may be an alkyl group substituted with 1 to 4 fluorine atoms, or the alkyl group may be an alkyl group substituted with a fluoroalkyl group.
  • alkoxy refers to an oxy group substituted with an alkyl group.
  • the preferred alkoxy group is an alkoxy group having 1 to 6 carbon atoms, more preferably an alkoxy group having 1 to 4 carbon atoms, and more preferably an alkoxy group having 1 to 3 carbon atoms.
  • alkoxy groups include, but are not limited to, methoxy, ethoxy, propoxy, and the like.
  • the alkoxy group may be substituted by one or more substituents, for example by halogen or haloalkyl.
  • the alkoxy group may be an alkyl group substituted with 1 to 4 fluorine atoms, or the alkyl group may be an alkyl group substituted with a fluoroalkyl group.
  • an alkoxy group may be substituted with one or more amino, wherein the amino group may be substituted with one or two lower alkyl groups, for example C 1 -C 3 alkyl, preferably methyl.
  • alkenyl generally denotes a monovalent hydrocarbon radical having at least one double bond, usually containing from 2 to 8 carbon atoms, preferably from 2 to 6 carbon atoms, and may be straight or branched.
  • alkenyl groups include, but are not limited to, ethenyl, propenyl, isopropenyl, butenyl, isobutenyl, hexenyl, and the like.
  • alkynyl generally denotes a monovalent hydrocarbon radical having at least one triple bond, usually containing from 2 to 8 carbon atoms, preferably from 2 to 6 carbon atoms, more usually from 2 to 4 carbon atoms, and may be straight-chain Or branching.
  • Alkenyl example package Including ethynyl, propynyl, isopropynyl, butynyl, isobutynyl, hexynyl and the like.
  • halogen means fluoro, chloro, bromo or iodo.
  • aryl refers to a monocyclic, bicyclic or tricyclic aromatic group containing from 6 to 14 carbon atoms, including phenyl, naphthyl, phenanthryl, anthryl, fluorenyl, fluorenyl, tetrahydronaphthalene. Base, indanyl group, and the like.
  • the aryl group may be optionally substituted with from 1 to 5 (e.g., 1, 2, 3, 4 or 5) substituents selected from the group consisting of halogen, C 1-4 aldehyde, C 1-6 alkyl, cyanide Base, nitro, amino, hydroxy, hydroxymethyl, halogen substituted alkyl (eg trifluoromethyl), halogen substituted alkoxy (eg trifluoromethoxy), carboxyl, C 1-4 alkoxy , ethoxycarbonyl, N(CH 3 ), C 1-4 acyl, etc., heterocyclic or heteroaryl, and the like.
  • substituents selected from the group consisting of halogen, C 1-4 aldehyde, C 1-6 alkyl, cyanide Base, nitro, amino, hydroxy, hydroxymethyl, halogen substituted alkyl (eg trifluoromethyl), halogen substituted alkoxy (eg trifluoromethoxy), carboxyl, C 1-4 alkoxy
  • heterocyclyl includes, but is not limited to, a 5- or 6-membered heterocyclic group containing from 1 to 3 heteroatoms selected from O, S or N, including but not limited to furyl, thienyl, pyrrolyl, Pyrrolidinyl, pyrazolyl, imidazolyl, triazolyl, oxazolyl, pyranyl, pyridyl, pyrimidinyl, pyrazinyl, piperidinyl, morpholinyl and the like.
  • heterocyclic group may be optionally substituted, e.g.
  • haloalkyl e.g., C 1 -C 3 alkyl or C 1 -C 3 haloalkyl
  • halogen e.g. , F, Cl, Br or I
  • Heterocyclyl as used herein may also be further substituted by a heterocyclic group, for example, a piperidinyl group as used herein may be further substituted with piperazinyl, and the piperazinyl group may be further substituted, for example by one or more Lower alkyl or haloalkyl (for example, C 1 -C 3 alkyl or C 1 -C 3 haloalkyl) or halogen (for example, F, Cl, Br or I).
  • Lower alkyl or haloalkyl for example, C 1 -C 3 alkyl or C 1 -C 3 haloalkyl
  • halogen for example, F, Cl, Br or I
  • aromatic heterocyclic means having from 5 to 14 ring atoms and having 6, 10 or 14 electrons are shared on the ring system. Further, the ring atom contained is a carbon atom and optionally 1-3 hetero atoms from oxygen, nitrogen, and sulfur.
  • Useful aromatic heterocyclic groups include piperazinyl, morpholinyl, piperidinyl, pyrrolidinyl, thienyl, furyl, pyranyl, pyrrolyl, imidazolyl, pyrazolyl, pyridyl, including but not limited to 2-pyridyl, 3-pyridyl and 4-pyridyl, pyrazinyl, pyrimidinyl and the like.
  • the aromatic heterocyclic group may be optionally substituted by one to five (for example, 1, 2, 3, 4 or 5) substituents selected from the group consisting of halogen, C 1-4 aldehyde group, C 1-6 linear chain Or branched alkyl, cyano, nitro, amino, hydroxy, hydroxymethyl, halogen substituted alkyl (eg trifluoromethyl), halogen substituted alkoxy (eg trifluoromethoxy), carboxyl, C 1-4 alkoxy, ethoxycarbonyl, N(CH 3 ) and C 1-4 acyl.
  • substituents selected from the group consisting of halogen, C 1-4 aldehyde group, C 1-6 linear chain Or branched alkyl, cyano, nitro, amino, hydroxy, hydroxymethyl, halogen substituted alkyl (eg trifluoromethyl), halogen substituted alkoxy (eg trifluoromethoxy), carboxyl, C 1-4 alkoxy, ethoxycarbon
  • acyloxy refers to a radical of the formula "-O-C(O)-R", wherein R may be selected from alkyl, alkenyl and alkynyl. The R can be optionally substituted.
  • “amido” refers to a group of the formula "-R'-NH-C(O)-R", wherein R' may be selected from hydrogen or alkyl, and R may be selected from alkyl, alkenyl. , alkynyl, NR c R d is substituted alkyl, NR c R d is substituted alkenyl and NR c R d group substituted alkynyl, halogen substituted alkyl, alkenyl substituted with cyano group, Wherein R c and R d may be selected from the group consisting of alkyl and alkenyl.
  • substituent to which it is modified may be optionally substituted with from 1 to 5 (eg, 1, 2, 3, 4 or 5) substituents selected from the group consisting of halogen, C. 1-4 aldehyde group, C 1-6 linear or branched alkyl group, cyano group, nitro group, amino group, hydroxyl group, hydroxymethyl group, halogen-substituted alkyl group (for example, trifluoromethyl group), halogen-substituted alkoxy group A group (e.g., trifluoromethoxy), a carboxyl group, a C 1-4 alkoxy group, an ethoxycarbonyl group, an N(CH 3 ) group, and a C 1-4 acyl group.
  • substituents selected from the group consisting of halogen, C. 1-4 aldehyde group, C 1-6 linear or branched alkyl group, cyano group, nitro group, amino group, hydroxyl group, hydroxymethyl group, halogen-
  • the compound of the present invention is a compound of the following formula I or a pharmaceutically acceptable salt thereof:
  • A is a benzene ring, a five- or six-membered heterocyclic ring, or a C 3 -C 8 cycloalkyl group;
  • R 1 is each independently selected from the group consisting of hydrogen, halogen, C 1 -C 3 alkoxy, C 1 -C 3 alkyl, C 1 -C 4 alkylamido, substituted piperazinyl, substituted homopiperazinyl, Substituted morpholinyl, substituted thiomorpholinyl, 4-N-methylpiperazinyl, 4-N-acetylpiperazinyl, 4-N,N-dimethylpiperidinyl, substituted piperazine a pyridine group, -NR a R b , wherein R a and R b are independently selected from an alkyl group and a nitrogen-containing alkyl group;
  • R 2 is each independently selected from the group consisting of:
  • R 3 is selected from the group consisting of hydrogen, C 1 -C 10 alkyl, substituted C 1 -C 10 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, optionally substituted C 3 a -C 8 cycloalkyl group, an optionally substituted aryl group, an optionally substituted benzyl group, an optionally substituted heterocyclic group, an optionally substituted aromatic heterocyclic group;
  • n is an integer from 0-7.
  • the A ring is a benzene ring such that the compound of the invention is as shown in Formula II below:
  • R 1 , R 2 and R 3 are as defined above; and m is an integer of 0-5.
  • the above benzene ring in the compound of the present invention may be substituted or unsubstituted, for example, the compound of the present invention may be as shown in the following formula III:
  • R 2 is selected from
  • R 3 is selected from C 1 -C 6 alkyl, preferably methyl or isopropyl; or phenyl substituted C 1 -C 6 alkyl, preferably benzyl;
  • R 4 , R 5 , R 6 , R 7 and R 8 are independently selected from the group consisting of
  • the above benzene rings in the compounds of the invention may be substituted as ortho, meta and/or para.
  • the above phenyl ring in the compounds of the invention is ortho- and para-substituted.
  • the above benzene rings in the compounds of the invention are ortho-, meta- and para-substituted.
  • R 5 and R 8 in the above formula III are H; or, R 5 , R 7 and R 8 are H.
  • Ketone compounds specific compounds are as follows:
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising therapeutically effective An amount of a compound of the invention, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.
  • Examples of pharmaceutically acceptable salts of the compounds of the invention include, but are not limited to, inorganic and organic acid salts such as the hydrochloride, hydrobromide, sulfate, citrate, lactate, tartrate, maleate salts. , fumarate, mandelate and oxalate; and inorganic and formed with bases such as sodium hydroxy, tris(hydroxymethyl)aminomethane (TRIS, tromethamine) and N-methyl glucosamine Organic base salt.
  • inorganic and organic acid salts such as the hydrochloride, hydrobromide, sulfate, citrate, lactate, tartrate, maleate salts. , fumarate, mandelate and oxalate
  • bases such as sodium hydroxy, tris(hydroxymethyl)aminomethane (TRIS, tromethamine) and N-methyl glucosamine Organic base salt.
  • the compound of the present invention or a pharmaceutically acceptable salt thereof is orally administered to a mammal daily in an amount of from about 0.0025 to 50 mg/kg body weight. Preferably, however, it is about 0.01 to 10 mg per kilogram of oral administration.
  • a unit oral dose can include from about 0.01 to 50 mg, preferably from about 0.1 to 10 mg, of a compound of the invention.
  • the unit dose may be administered one or more times per day in one or more tablets, each tablet containing from about 0.1 to 50 mg, conveniently from about 0.25 to 10 mg of the compound of the invention or a solvate thereof.
  • the pharmaceutical composition of the present invention can be formulated into a form suitable for various administration routes, including but not limited to being formulated for parenteral, subcutaneous, intravenous, intramuscular, intraperitoneal, transdermal, oral, intrathecal, intracranial A form of administration, intranasal or topical, for the treatment of tumors and other diseases.
  • the amount administered is an amount effective to ameliorate or eliminate one or more conditions.
  • an effective amount is an amount sufficient to ameliorate or in some way alleviate the symptoms associated with the disease.
  • Such doses can be administered as a single dose or can be administered according to an effective therapeutic regimen.
  • the amount administered may cure the disease, but administration is usually to improve the symptoms of the disease. Repeated administration is generally required to achieve the desired improvement in symptoms.
  • the dosage of the drug will be determined by the age of the patient, the health and weight, the type of concurrent treatment, the frequency of treatment, and the desired therapeutic benefit.
  • the pharmaceutical preparation of the present invention can be administered to any mammal as long as they can obtain the therapeutic effect of the compound of the present invention.
  • the most important of these mammals is humans.
  • the compounds of the invention or pharmaceutical compositions thereof are useful in the treatment of a variety of diseases mediated by epidermal growth factor receptor kinase (EGFR).
  • EGFR epidermal growth factor receptor kinase
  • the disease mediated by EGFR is various cancers.
  • the cancer includes, but is not limited to, non-small cell lung cancer, small cell lung cancer, lung adenocarcinoma, lung squamous cell carcinoma, breast cancer, prostate cancer, glioma, ovarian cancer, head and neck squamous cell carcinoma, cervical cancer, esophagus Cancer, liver cancer, kidney cancer, pancreatic cancer, colon cancer, skin cancer, leukemia, lymphoma, gastric cancer, multiple myeloma and solid tumors.
  • the pharmaceutical preparations of the invention can be made in a known manner. For example, it is manufactured by a conventional mixing, granulating, tableting, dissolving, or freeze drying process. In the manufacture of oral formulations, the mixture can be selectively milled by combining the solid adjuvant with the active compound. If necessary or necessary, after adding an appropriate amount of auxiliary agent, the mixture of particles is processed to obtain a tablet or tablet core.
  • Suitable excipients are, in particular, fillers, such as sugars such as lactose or sucrose, mannitol or sorbitol; cellulose preparations or calcium phosphates, such as tricalcium phosphate or calcium hydrogen phosphate; and binders, such as starch pastes, including corn starch. , wheat starch, rice starch, potato starch, gelatin, tragacanth, methyl cellulose, hydroxypropyl methyl cellulose, sodium carboxymethyl cellulose, or polyvinylpyrrolidone.
  • fillers such as sugars such as lactose or sucrose, mannitol or sorbitol
  • cellulose preparations or calcium phosphates such as tricalcium phosphate or calcium hydrogen phosphate
  • binders such as starch pastes, including corn starch. , wheat starch, rice starch, potato starch, gelatin, tragacanth, methyl cellulose, hydroxypropyl methyl cellulose, sodium carboxymethyl
  • a disintegrating agent such as the above-mentioned starch, and carboxymethyl starch, crosslinked polyvinylpyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate may be added.
  • Adjuvants are especially flow regulators and lubricants, for example, silica, talc, stearates such as calcium magnesium stearate, stearic acid or polyethylene glycol.
  • the tablet core can be provided with a suitable coating that is resistant to gastric juice. For this, it can be applied Concentrate the saccharide solution.
  • This solution may contain gum arabic, talc, polyvinylpyrrolidone, polyethylene glycol and/or titanium dioxide, a lacquer solution and a suitable organic solvent or solvent mixture.
  • a suitable cellulose solution such as cellulose acetate phthalic acid or hydroxypropyl methylcellulose phthalic acid can be used.
  • a dye or pigment can be added to the coating of the tablet or tablet core. For example, a combination for identifying or for characterizing the dosage of an active ingredient.
  • the invention further provides a method of treating an EGFR mediated disease, the method comprising administering to a subject in need thereof a compound or pharmaceutical composition of the invention.
  • Methods of administration include, but are not limited to, various methods of administration well known in the art, which can be determined based on the actual circumstances of the patient. These methods include, but are not limited to, parenteral, subcutaneous, intravenous, intramuscular, intraperitoneal, transdermal, buccal, intrathecal, intracranial, nasal or topical routes of administration.
  • the invention also encompasses the use of a compound of the invention in the manufacture of a medicament for preventing or treating an EGFR mediated disease or inhibiting EGFR activity.
  • the compound provided by the present invention is a novel structure of pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione;
  • the compound provided by the present invention has excellent inhibitory activity against mutant EGFR or EGFR mutant cancer cells
  • the compound provided by the present invention lays a foundation for the development of an EGFR-targeted drug capable of selectively inhibiting T790M mutation and can overcome clinical drug resistance, and has great industrialization and commercialization prospects as well as market value and significant economic benefits.
  • Reagents and conditions (a) DIPEA, CH 3 CN, reflux; (b) ArNH 2 , CH 3 CN, reflux; (c) NaOH, THF, reflux; (d) R 3 NH 2 , HATU, DIPEA, DMF; (e) K 2 CO 3 , CDI, THF, reflux; (f) trifluoroacetic acid, CH 2 Cl 2 , 0 ° C - room temperature; (g) acid chloride, Et 3 N, CH 2 Cl 2 , 0 ° C - room temperature.
  • 2,4-Dichloro-5-nitropyrimidine (2.210 g, 10 mmol), DIPEA (1.290 g, 10 mmol) was weighed in a 50 mL single-necked flask and dissolved in 15 mL of acetonitrile. Further, tert-butyl (3-aminophenyl)carbamate (2.080 g, 10 mmol) was dissolved in 10 mL of acetonitrile, and the mixture was added dropwise to the mixture.
  • TLC is traced to the conversion of the raw materials, cooled to room temperature, adjusted to pH with dilute hydrochloric acid, suction filtered, washed with water, and dried with filter cake to give 4-((3-((tert-butoxycarbonyl)amino)phenyl)amino) 2-(phenylamino)pyrimidine-5-carboxylic acid 1.499 g, yield 89%.
  • Reagents and conditions (a)-(e) as previously described; (f) N, N, N'-trimethylethylenediamine, K 2 CO 3 , DMSO; (n) Zn, NH 4 Cl, CH 3 OH; (o) acid chloride, Et 3 N, CH 2 Cl 2 , 0 ° C - room temperature.
  • In vitro enzyme activity assay Wild type and various mutant (T790M, L858/T790M) EGFR were purchased from Invitrogen. Ten concentration gradients from 5.1 x 10 -11 mol/L to 1.0 x 10 -6 mol/L were set for all compounds to be tested.
  • the concentration of different kinases was determined by optimization experiments. The corresponding concentrations were: EGFR (PV3872, Invitrogen) 0.287 ⁇ g/ ⁇ L, EGFR-T790M (PV4803, Invitrogen) 0.174 ⁇ g/ ⁇ L, EGFR-L858R/T790M (PV4879, Invitrogen) 0.055 ⁇ g. / ⁇ L.
  • the compound was diluted three times from 5.1 x 10 -9 M to 1 x 10 -4 M in DMSO. 4 ⁇ L of the compound was dissolved in 96 ⁇ L of water to obtain a 4x compound solution.
  • kinase/peptide mixture contained 2x kinase, 4 ⁇ M tyrosine 4 peptide ready for use.
  • the 10 ⁇ L kinase reaction included 2.5 ⁇ L of compound solution, 5 ⁇ L of kinase/peptide mixture, and 2.5 ⁇ L of ATP solution. 5 ⁇ L of phosphorylated peptide solution was used instead of the kinase/peptide mixture as a 100% phosphorylation control.
  • H1975 non-small cell lung cancer cells, EGFR L858R/T790M
  • A431 non-small cell lung cancer cells, EGFR wild type
  • the cells were exposed to the treatment conditions for 72 hours, and the number of cells used in each cell of each cell was adjusted according to the absorbance value (absorbance value at 490 nm of 1.3-2.2).
  • Six concentration gradients (0.1 nM - 10 [mu]M) were set for the compounds to be tested, and at least 6 sets of parallel controls were used for each concentration value.
  • H1975, A431 cells were cultured in the corresponding medium, and the cells were passaged at least twice after resuscitation, and then used for experimental use. The log phase cells were trypsinized and resuspended in culture. H1975 (1000 cells per well), A431 (2000 cells per well) were seeded in 96-well plates in a volume of 100 ⁇ L; 6 sets of parallel and 7 columns were set. The plates were placed in an incubator at 37 ° C in a 5% carbon dioxide overnight.
  • the compound was dissolved in DMSO to a concentration of 10 ⁇ M per liter, and then the compound concentration was gradually diluted to obtain a compound concentration of 10 ⁇ M, 1 ⁇ M, 0.1 ⁇ M, 0.01 ⁇ M, 0.001 ⁇ M, and 0.0001 ⁇ M per liter, respectively.
  • 2 ⁇ L of the compound solution was added to 998 ⁇ L of the medium, and the mixture was thoroughly mixed. 100 ⁇ L of the mixture was added to a 96-well plate. 2 ⁇ L of DMSO was used instead of the compound solution as a 0% inhibition control. After incubation for 68 hours, 20 ⁇ L of MTT (5 mg/mL) was added.
  • the compound of the present invention has a higher difference in the ability to inhibit the proliferation of EGFR mutant cancer cells (H1975) and EGFR wild-type cancer cells (A431) than the mutant EGFR and wild-type EGFR kinases, thereby It is suggested that the compounds of the present invention have better differential toxicity in vivo, and may be a third-generation EGFR-targeted drug that selectively inhibits T790M mutation, overcomes clinical resistance, or is more modified to obtain more active and/or differential toxicity. The basis of better compounds.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明涉及作为EGFR抑制剂的嘧啶并嘧啶二酮衍生物及其应用。具体而言，本发明涉及式（I）所示化合物、含有式（I）化合物的药物组合物及所述化合物在制备治疗EGFR相关疾病或抑制EGFR的药物中的用途。

Description

作为EGFR抑制剂的嘧啶并嘧啶二酮衍生物及其应用 技术领域
本发明涉及药物化学领域；具体地说，本发明涉及新型的嘧啶并嘧啶二酮衍生物，其合成方法及其作为EGFR抑制剂在制备肿瘤相关疾病的药物中的应用。
背景技术
癌症亦称恶性肿瘤，是以细胞异常增殖及转移为特点的一大类疾病，具有发病率高和死亡率高的特点，是威胁人类健康，导致死亡的恶性疾病之一。研究数据表明，2008年全球有1270万癌症患者，其中死亡人数高达700余万。而全世界20％的新发肿瘤病人在中国，24％的肿瘤死亡病人在中国。如果不采取有效措施预防，或拿出更优的治疗方案，预计到2030年，世界范围内每年将出现2600万新增癌症病例，癌症死亡人数将达到1700万。在现有的癌症中，肺癌是目前世界范围内发病率和死亡率最高的恶性肿瘤，其中非小细胞肺癌(NSCLC)占肺癌患者的80％以上。据世界卫生组织(WHO)预测，到2025年，我国每年新增肺癌病例将超过100万。一旦被确诊为肺癌，患者便只有渺茫的生存前景，5年生存率不到15％。
从20世纪80年代开始，随着肿瘤分子生物学研究的深入，肿瘤发生、发展的分子机制日益清晰。在诸多诱发癌症的因素中，癌细胞中由基因突变引起的高表达的某些蛋白激酶是导致其信号转导通路异常的主要因素之一。蛋白质酪氨酸激酶是信号传递过程中的重要因子，参与一系列细胞活动，与细胞生长、分化、增殖密切相关。它催化ATP的γ磷酸基转移到许多重要蛋白质的酪氨酸残基上，使酚羟基磷酸化，从而传递信号。因此，发展选择性的蛋白激酶抑制剂来阻断或者调控由于这些信号通路异常产生的疾病已经被视为抗肿瘤药物开发的一个有效的研究策略。在众多的酪氨酸激酶中，表皮生长因子受体酪氨酸激酶(epidermal growth factor receptor tyrosine kinase,EGFR)是不可或缺的重要组成部分。EGFR由1186个氨基酸组成，编码一个分子量为170-kDa的跨膜糖蛋白。EGFR能够介导多条信号转导通路，将胞外信号传递到胞内，对正常细胞和肿瘤细胞的增殖、分化和凋亡均发挥重要的调节作用(Cell,2000,100,113-127)。EGFR是许多正常上皮组织(如皮肤和毛囊)的组成性表达成分，而在大部分实体瘤中，EGFR存在过表达或者高表达。例如，在肺癌中，EGFR的表达率达到40～80％。因此选择性地抑制EGFR，干扰其介导的信号转导途径，可以达到治疗肺癌的目的，为靶向治疗肺癌开辟了一条可行之路。
临床治疗上，结合传统的放疗、化疗，以EGFR靶向药物如吉非替尼(Iressa)、厄洛替尼(Tarceva)等进行一线药物在肺癌治疗中被证明是非常有效的。然而，临床实践表明：大部分非小细胞肺癌患者在使用吉非替尼或厄洛替尼治疗之后，会在6-12月内出现获得性耐药。其中大约50％病例的耐药性与EGFR激酶结构域中一个氨基酸残基的突变(790位苏氨酸残基突变为甲硫氨酸，T790M)有关(The New England Journal of Medicine,2005, 352,786-792)。T790M突变导致抑制剂与EGFR结合时产生空间位阻或者增加EGFR与ATP的亲和力，使得这类可逆性结合的竞争性抑制剂的抗癌效果大大减弱。耐药性的产生不但降低了病人对药物的敏感性，也大大降低了肿瘤患者的生存质量。为了克服T790M突变引起的耐药性，一系列不可逆ATP竞争性抑制剂(如CI-1033、HKI-272、PF00299804等)已进入临床研究阶段。不可逆抑制剂含有一个迈克尔受体片段，能与EGFR的ATP结合位点的一个保守氨基酸残基(Cys797)形成共价键，从而获得了比可逆性抑制剂更强的EGFR结合亲和力。尽管如此，由于此类药物对野生型和突变型EGFR选择性较差，因此其最大耐受量(MTD)较低，临床实验效果并不明显。
因此，研究开发选择性抑制T790M突变，克服临床耐药的第三代EGFR靶向药物具有重大的临床意义和应用前景。
发明内容
本发明的目的是提供能够选择性抑制T790M突变的嘧啶并嘧啶二酮衍生物作为EGFR抑制剂。
本发明的另一目的是提供包含上述化合物的药物组合物。
本发明还有一目的是提供上述化合物在制备治疗EGFR相关疾病或抑制EGFR的药物中的用途。
在第一方面，本发明提供通式I所示的化合物或其药学上可接受的盐：
Figure PCTCN2016073726-appb-000001
式中，A为苯环、五元或六元杂环、C3-C8环烷基；
R1各自独立选自氢、卤素、C1-C3烷氧基、C1-C3烷基、C1-C4烷基酰胺基、取代的哌嗪基、取代的高哌嗪基、取代的吗啉基、取代的硫代吗啉基、4-N-甲基哌嗪基、4-N-乙酰基哌嗪基、4-N,N-二甲基哌啶基、取代的哌啶基、-NRaRb，其中，Ra和Rb可独立选自烷基和含氮烷基；
R2各自独立选自以下基团：
Figure PCTCN2016073726-appb-000002
R3选自下组：氢、C1-C10烷基，取代的C1-C10烷基、C2-C6链烯基、C2-C6炔基、任选取代的C3-C8环烷基、任选取代的芳基、任选取代的苄基、任选取代的杂环基、任选取代的芳杂环基；
B选自下组：
Figure PCTCN2016073726-appb-000003
m为0-7的整数。
在具体的实施方式中，所述化合物如通式II所示：
Figure PCTCN2016073726-appb-000004
式中，B、R1、R2、R3如以上所限定；
m为0-5的整数。
在具体的实施方式中，所述化合物如通式III所示：
Figure PCTCN2016073726-appb-000005
式中，
R2选自
Figure PCTCN2016073726-appb-000006
R3选自C1-C6烷基，优选甲基或异丙基；或苯基取代的C1-C6烷基，优选苄基；R4、R5、R6、R7和R8独立选自下组：
Figure PCTCN2016073726-appb-000007
Figure PCTCN2016073726-appb-000008
和C1-C3烷基。
在具体的实施方式中，R5和R8为H；或者，R5、R7和R8为H。
在具体的实施方式中，本发明提供选自下组的化合物或其药学上可接受的盐：
Figure PCTCN2016073726-appb-000009
Figure PCTCN2016073726-appb-000010
Figure PCTCN2016073726-appb-000011
在第二方面，本发明提供一种药物组合物，所述药物组合物含有本发明第一方面所述的化合物或其药学上可接受的盐，以及药学上可接受的载体或赋形剂。
在优选的实施方式中，所述药物组合物是适于口服的剂型，包括但不限于片剂、溶液剂、混悬液、胶囊剂、颗粒剂、粉剂。
在第三方面，本发明提供本发明第一方面所述的化合物在制备治疗或预防EGFR介导的疾病，或抑制EGFR的药物中的用途。
在具体的实施方式中，所述EGFR介导的疾病为癌症。
在具体的实施方式中，所述癌症选自下组：非小细胞肺癌、小细胞肺癌、肺腺癌、肺鳞癌、乳腺癌、前列腺癌、神经胶质细胞瘤、卵巢癌、头颈部鳞癌、宫颈癌、食管癌、肝癌、肾癌、胰腺癌、结肠癌、皮肤癌、白血病、淋巴瘤、胃癌、多发性骨髓癌和实体瘤。
在第四方面，本发明提供利用本发明第一方面所述的化合物治疗或预防EGFR介导的疾病方法。
在优选的实施方式中，所述EGFR介导的疾病为癌症；优选地，所述癌症选自下组：非小细胞肺癌、小细胞肺癌、肺腺癌、肺鳞癌、乳腺癌、前列腺癌、神经胶质细胞瘤、卵巢癌、头颈部鳞癌、宫颈癌、食管癌、肝癌、肾癌、胰腺癌、结肠癌、皮肤癌、白血病、淋巴瘤、胃癌、多发性骨髓癌和实体瘤。
应理解，在本发明范围内中，本发明的上述各技术特征和在下文(如实施例)中具体描述的各技术特征之间都可以互相组合，从而构成新的或优选的技术方案。限于篇幅，在此不再一一累述。
具体实施方式
发明人经过广泛而深入的研究，出乎意料地发现一批结构全新的嘧啶并嘧啶二酮衍生物，这些衍生物能够选择性抑制EGFR T790M突变，对EGFRT790M/L858R激酶抑制活性的IC50值达到nM级别；对癌细胞(EGFRL858R/T790M突变)增殖的抑制活性IC50值达到μM级别。在此基础上完成了本发明。
本发明人合成了具有EGFR抑制活性的候选化合物。对得到的候选化合物进行结构优化，设计并合成了一系列未见文献报道的嘧啶并[4,5-d]嘧啶-2,4(1H,3H)-二酮类化合物，并进行了结构表征。对此系列化合物进行了分子水平和细胞水平的活性测试，得到一批具有选择性抑制EGFR T790M突变的化合物。其中化合物007对EGFRT790M/L858激酶抑制活性IC50为30.0nM，H1975(非小细胞肺癌细胞，EGFRL858R/T790M)细胞增殖抑制活性IC50为0.23μM。
术语定义
除非另有明确的定义，本文的基团均是可以任选取代的基团。为说明的目的，本文中涉及到的一些基团定义如下，但不限于此：
本文中，“烷基”指碳链长度为1-10个碳原子的饱和的支链或直链烷基，优选的烷基包括长2-8个、1-6个、1-4个、3-8个、1-3个碳原子不等的烷基。烷基的例子包括但不限于：甲基、乙基、正丙基、异丙基、正丁基、异丁基、庚基等。烷基可以被1个或多个取代基取代，例如被卤素或卤代烷基取代。例如，烷基可以是被1-4个氟原子取代的烷基，或者烷基可以是被氟代烷基取代的烷基。
本文中，“烷氧基”指被烷基取代的氧基。优选的烷氧基是长1-6个碳原子的烷氧基，更优选为长1-4个碳原子的烷氧基，更优选为长1-3个碳原子的烷氧基。烷氧基的例子包括但不限于：甲氧基、乙氧基、丙氧基等。烷氧基可以被1个或多个取代基取代，例如被卤素或卤代烷基取代。例如，烷氧基可以是被1-4个氟原子取代的烷基，或者烷基可以是被氟代烷基取代的烷基。再例如，烷氧基可以被一个或多个氨基取代，其中所述氨基可以被一个或两个低级烷基，例如C1-C3烷基，优选甲基取代。
本文中，“链烯基”通常表示具有至少一个双键的单价烃基，通常含有2-8个碳原子，优选含有2-6个碳原子，可以是直链或支链。链烯基的例子包括但不限于乙烯基、丙烯基、异丙烯基、丁烯基、异丁烯基、己烯基等等。
本文中，“炔基”通常表示具有至少一个三键的单价烃基，通常含有2-8个碳原子，优选含有2-6个碳原子，更通常含有2-4个碳原子，可以是直链或支链。链烯基的例子包 括乙炔基、丙炔基、异丙炔基、丁炔基、异丁炔基、己炔基等。
本文中，“卤素”指氟、氯、溴或碘。
本文中，“芳基”指含有6到14个碳原子的单环、双环或三环芳族基团，包括苯基、萘基、菲基、蒽基、茚基、茀基、四氢化萘基、二氢化茚基等。芳基可任选地被1-5个(例如，1、2、3、4或5个)选自以下的取代基取代：卤素、C1-4醛基、C1-6烷基、氰基、硝基、氨基、羟基、羟甲基、卤素取代的烷基(例如三氟甲基)、卤素取代的烷氧基(例如三氟甲氧基)、羧基、C1-4烷氧基、乙氧甲酰基、N(CH3)和C1-4酰基等、杂环基或杂芳基等。
本文所用“杂环基”包括但不限于含有1-3个选自O、S或N的杂原子的5元或6元杂环基团，包括但不限于呋喃基、噻吩基、吡咯基、吡咯烷基、吡唑基、咪唑基、三唑基、噁唑基、吡喃基、吡啶基、嘧啶基、吡嗪基、哌啶基、吗啉基等。本文所用的“杂环基”可以是任选取代的，例如被一个或多个低级烷基或卤代烷基(例如，C1-C3烷基或C1-C3卤代烷基)或卤素(例如，F、Cl、Br或I)取代。本文所用的“杂环基”还可以被杂环基进一步取代，例如本文所用的哌啶基可以被哌嗪基进一步取代，而所述哌嗪基上还可作进一步取代，例如被一个或多个低级烷基或卤代烷基(例如，C1-C3烷基或C1-C3卤代烷基)或卤素(例如，F、Cl、Br或I)取代。
本文所用“芳杂环基”是指含有5-14个环原子，并且有6个、10个或14个电子在环体系上共用。而且所含环原子是碳原子和从氧、氮、硫中任选的1-3个杂原子。有用的芳杂环基包括哌嗪基、吗啉基、哌啶基、吡咯烷基、噻吩基、呋喃基、吡喃基、吡咯基、咪唑基、吡唑基、吡啶基、包括但不限制于2-吡啶基、3-吡啶基和4-吡啶基、吡嗪基、嘧啶基等。
芳杂环基可任选地被1-5个(例如，1、2、3、4或5个)选自以下的取代基取代：卤素、C1-4醛基、C1-6直链或支链烷基、氰基、硝基、氨基、羟基、羟甲基、卤素取代的烷基(例如三氟甲基)、卤素取代的烷氧基(例如三氟甲氧基)、羧基、C1-4烷氧基、乙氧甲酰基、N(CH3)和C1-4酰基。
本文中，“酰氧基”指结构式为“-O-C(O)-R”的基团，其中，R可选自烷基、链烯基和炔基。所述R可任选地被取代。
本文中，“酰氨基”指结构式为“-R’-NH-C(O)-R”的基团，其中，R’可选自氢或烷基，R可选自烷基、链烯基、炔基、被NRcRd取代的烷基、被NRcRd取代的链烯基和NRcRd取代的炔基、被卤素取代的烷基、被氰基取代的链烯基，其中，Rc和Rd可选自烷基和链烯基。
本文中，“任选取代的”指其所修饰的取代基可任选地被1-5个(例如，1、2、3、4或5个)选自以下的取代基取代：卤素、C1-4醛基、C1-6直链或支链烷基、氰基、硝基、氨基、羟基、羟甲基、卤素取代的烷基(例如三氟甲基)、卤素取代的烷氧基(例如三氟甲氧基)、羧基、C1-4烷氧基、乙氧甲酰基、N(CH3)和C1-4酰基。
本发明的化合物
本发明的化合物是以下通式I所示的化合物或其药学上可接受的盐：
Figure PCTCN2016073726-appb-000012
式中，A为苯环、五元或六元杂环、C3-C8环烷基；
R1各自独立选自氢、卤素、C1-C3烷氧基、C1-C3烷基、C1-C4烷基酰胺基、取代的哌嗪基、取代的高哌嗪基、取代的吗啉基、取代的硫代吗啉基、4-N-甲基哌嗪基、4-N-乙酰基哌嗪基、4-N,N-二甲基哌啶基、取代的哌啶基、-NRaRb，其中，Ra和Rb可独立选自烷基和含氮烷基；
R2各自独立选自以下基团：
Figure PCTCN2016073726-appb-000013
R3选自下组：氢、C1-C10烷基，取代的C1-C10烷基、C2-C6链烯基、C2-C6炔基、任选取代的C3-C8环烷基、任选取代的芳基、任选取代的苄基、任选取代的杂环基、任选取代的芳杂环基；
B选自下组：
Figure PCTCN2016073726-appb-000014
m为0-7的整数。
在具体的实施方式中，A环为苯环，从而本发明的化合物如以下通式II所示：
Figure PCTCN2016073726-appb-000015
式中，B、R1、R2、R3如上所述；和m为0-5的整数。
在优选的实施方式中，本发明的化合物中的上述苯环可以是取代或未取代的，例如，本发明的化合物可以如以下通式III所示：
Figure PCTCN2016073726-appb-000016
式中，
R2选自
Figure PCTCN2016073726-appb-000017
R3选自C1-C6烷基，优选甲基或异丙基；或苯基取代的C1-C6烷基，优选苄基；
R4、R5、R6、R7和R8独立选自下组：
Figure PCTCN2016073726-appb-000018
Figure PCTCN2016073726-appb-000019
和C1-C3烷基。
在进一步的实施方式中，本发明的化合物中的上述苯环可以作邻位取代、间位取代和/或对位取代。在优选的实施方式中，本发明的化合物中的上述苯环是邻位取代和对位取代的。在另一优选的实施方式中，本发明的化合物中的上述苯环是邻位取代、间位取代和对位取代的。在具体的实施方式中，以上通式III中的R5和R8为H；或者，R5、R7和R8为H。
本发明人合成得到了一系列结构未见文献报道的嘧啶并[4,5-d]嘧啶-2,4(1H,3H)-二 酮类化合物，具体的化合物如下所示：
Figure PCTCN2016073726-appb-000020
Figure PCTCN2016073726-appb-000021
在本发明的化合物的基础上，本发明提供一种药物组合物，该组合物含有治疗有效 量的本发明的化合物或其药学上可接受的盐，以及药学上可接受的载体或赋形剂。
本发明化合物的药学上可接受的盐的例子包括但不限于无机和有机酸盐，例如盐酸盐、氢溴酸盐、硫酸盐、柠檬酸盐、乳酸盐、酒石酸盐、马来酸盐、富马酸盐、扁桃酸盐和草酸盐；以及与碱例如钠羟基、三(羟基甲基)胺基甲烷(TRIS，胺丁三醇)和N-甲基葡糖胺形成的无机和有机碱盐。
虽然每个人的需求各不相同，本领域技术人员可确定本发明药物组合物中每种活性成分的最佳剂量。一般情况下，本发明的化合物或其药学上可接受的盐，对哺乳动物每天口服给药，药量按照约0.0025到50毫克/公斤体重。但最好是每公斤口服给药约0.01到10毫克。例如，单位口服剂量可以包括约0.01到50毫克，最好是约0.1到10毫克的本发明化合物。单位剂量可给予一次或多次，每天为一片或多片，每片含有约0.1到50毫克，合宜地约0.25到10毫克的本发明化合物或其溶剂化物。
本发明的药物组合物可被配制成适合各种给药途径的制剂形式，包括但不限于被配制成用于肠外，皮下，静脉，肌肉，腹腔内，透皮，口腔，鞘内，颅内，鼻腔或外用途径给药的形式，用于治疗肿瘤和其他疾病。给药量是有效地改善或消除一个或多个病症的药量。对于特定疾病的治疗，有效量是足以改善或以某些方式减轻与疾病有关的症状的药量。这样的药量可作为单一剂量施用，或者可依据有效的治疗方案给药。给药量也许可治愈疾病，但是给药通常是为了改善疾病的症状。一般需要反复给药来实现所需的症状改善。药的剂量将根据病人的年龄，健康与体重，并行治疗的种类，治疗的频率，以及所需治疗效益来决定。
本发明的药物制剂可以给予任何哺乳动物，只要他们能获得本发明化合物的治疗效果。在这些哺乳动物中最为重要的是人类。
本发明的化合物或其药物组合物可用于治疗各种由表皮生长因子受体激酶(EGFR)介导的疾病。本文中，由EGFR介导的疾病为各种癌症。所述癌症包括但不限于：非小细胞肺癌、小细胞肺癌、肺腺癌、肺鳞癌、乳腺癌、前列腺癌、神经胶质细胞瘤、卵巢癌、头颈部鳞癌、宫颈癌、食管癌、肝癌、肾癌、胰腺癌、结肠癌、皮肤癌、白血病、淋巴瘤、胃癌、多发性骨髓癌及实体瘤。
本发明的药物制剂可用已知的方式制造。例如，由传统的混合，制粒，制锭，溶解，或冷冻干燥过程制造。制造口服制剂时，可结合固体辅料和活性化合物，选择性研磨混合物。如果需要或必要时加入适量助剂后，加工颗粒混合物，获得片剂或锭剂芯。
合适的辅料特别是填料，例如糖类如乳糖或蔗糖，甘露醇或山梨醇；纤维素制剂或钙磷酸盐，例如磷酸三钙或磷酸氢钙；以及粘结剂，例如淀粉糊，包括玉米淀粉，小麦淀粉，大米淀粉，马铃薯淀粉，明胶，黄芪胶，甲基纤维素，羟丙基甲基纤维素，羧甲基纤维素钠，或聚乙烯吡咯烷酮。如果需要，可增加崩解剂，比如上面提到的淀粉，以及羧甲基淀粉，交联聚乙烯吡咯烷酮，琼脂，或褐藻酸或其盐，如海藻酸钠。辅助剂特别是流动调节剂和润滑剂，例如，硅石，滑石，硬脂酸盐类，如镁硬脂酸钙，硬脂酸或聚乙二醇。如果需要，可以給锭剂核芯提供可以抵抗胃液的合适包衣。为此，可以应用 浓缩糖类溶液。这个溶液可以含有阿拉伯树胶，滑石，聚乙烯吡咯烷酮，聚乙二醇和/或二氧化钛，漆溶液和合适的有机溶剂或溶剂混合物。为了制备耐胃液的包衣，可使用适当的纤维素溶液，例如醋酸纤维素邻苯二甲酸或羟丙基甲基纤维素邻苯二甲酸。可向药片或锭剂核芯的包衣加入染料或色素。例如，用于识别或为了表征活性成分剂量的组合。
基于上述化合物和药物组合物，本发明进一步提供一种治疗EGFR介导的疾病的方法，该方法包括给予需要的对象以本发明的化合物或药物组合物。
给药方法包括但不限于本领域周知的各种给药方法，可根据患者的实际情况加以确定。这些方法包括但不限于肠外、皮下、静脉、肌肉、腹腔内、透皮、口腔、鞘内、颅内、鼻腔或外用途径给药。
本发明也包括本发明化合物在制备预防或治疗EGFR介导的疾病或抑制EGFR活性的药物中的用途。
本发明的优点：
1.本发明提供的化合物是一种结构全新的嘧啶并[4,5-d]嘧啶-2,4(1H,3H)-二酮类化合物；
2.本发明提供的化合物对突变型EGFR或EGFR突变的癌细胞具有优异的抑制活性；
3.本发明提供的化合物为开发能选择性抑制T790M突变的，能克服临床耐药的EGFR靶向药物奠定了基础，具备极大的产业化和商品化前景以及市场价值，经济效益显著。
以下结合具体实施案例对本发明的技术方案进一步描述，但以下实施案例不构成对本发明的限制，所有依据本发明的原理和技术手段采用的各种施用方法，均属于本发明范围。下列实施例中未注明具体条件的实验方法，通常按照常规条件，或按照制造厂商所建议的条件。除非另外说明，否则百分比和份数按重量计算。
材料与方法
本发明的嘧啶并[4,5-d]嘧啶-2,4(1H,3H)-二酮类化合物的合成如下所示：
Figure PCTCN2016073726-appb-000022
试剂和条件：(a)DIPEA,CH3CN,回流；(b)ArNH2,CH3CN,回流；(c)NaOH,THF,回流；(d)R3NH2,HATU,DIPEA,DMF；(e)K2CO3,CDI,THF,回流；(f)三氟乙酸,CH2Cl2,0℃–室温；(g)酰氯,Et3N,CH2Cl2,0℃–室温。
实施例1
上述步骤a-g的具体合成方法如下：
1. 4-((3-((叔丁氧基羰基)氨基)苯基)氨基)-2-氯嘧啶-5-甲酸乙酯的合成
Figure PCTCN2016073726-appb-000023
称取2,4-二氯-5-硝基嘧啶(2.210g,10mmol)、DIPEA(1.290g,10mmol)于50mL单口烧瓶，加入15mL乙腈溶解。另取(3-氨基苯基)氨基甲酸叔丁酯(2.080g,10mmol)溶于10mL乙腈，滴加到上述反应液中，滴加完回流2h。TLC跟踪至原料转化，冷却至室温，抽滤，乙腈洗涤，滤饼烘干，得4-((3-((叔丁氧基羰基)氨基)苯基)氨基)-2-氯嘧啶-5-甲酸乙酯3.371g，产率86％。1H NMR(400MHz,DMSO-d6)δ10.23(s,1H),9.50(s,1H),8.80(s,1H),7.70(s,1H),7.35(d,J＝8.0Hz,1H),7.29(t,J＝8.0Hz,1H),7.23(d,J＝8.0Hz,1H),4.38(q,J＝7.2Hz,2H),1.49(s,9H),1.36(t,J＝7.2Hz,3H).LC-MS:m/z:393.1(M+H)+.
2. 4-((3-((叔丁氧基羰基)氨基)苯基)氨基)-2-(苯基氨基)嘧啶-5-甲酸乙酯的合成
Figure PCTCN2016073726-appb-000024
称取4-((3-((叔丁氧基羰基)氨基)苯基)氨基)-2-氯嘧啶-5-甲酸乙酯(1.960g,5mmol)、苯胺(0.558g,6mmol)于100mL单口烧瓶，加入40mL乙腈溶解，升温回流3h。TLC跟踪原料转化，冷却至室温，抽滤，水洗，滤饼烘干，得4-((3-((叔丁氧基羰基)氨基)苯基)氨基)-2-(苯基氨基)嘧啶-5-甲酸乙酯1.930g，产率86％。1H NMR(400MHz,CDCl3)δ10.46(s,1H),8.76(s,1H),7.57(d,J＝8.0Hz,2H),7.36(t,J＝7.6Hz,3H),7.23(d,J＝8.0Hz,1H),7.16(t,J＝7.2Hz,1H),7.04(d,J＝7.6Hz,1H),6.36(s,1H),4.37(q,J＝7.2Hz,2H),1.54(s,9H),1.41(t,J＝7.2Hz,3H).LC-MS:m/z:450.4(M+H)+.
3. 4-((3-((叔丁氧基羰基)氨基)苯基)氨基)-2-(苯基氨基)嘧啶-5-甲酸的合成
Figure PCTCN2016073726-appb-000025
称取4-((3-((叔丁氧基羰基)氨基)苯基)氨基)-2-(苯基氨基)嘧啶-5-甲酸乙酯(1.796g,4mmol)于100mL单口烧瓶，加入30mL四氢呋喃溶解，滴加1M NaOH溶液10mL，升温至50℃，搅拌3h。TLC跟踪至原料转化，冷却至室温，加入稀盐酸调节pH至酸性，抽滤，水洗，滤饼烘干，得4-((3-((叔丁氧基羰基)氨基)苯基)氨基)-2-(苯基氨基)嘧啶-5-甲酸1.499g，产率89％。1H NMR(400MHz,DMSO-d6)δ10.44(s,1H),9.82(s,1H),9.36(s,1H),8.70(s,1H),7.69(d,J＝8.0Hz,2H),7.63(s,1H),7.43(s,1H),7.26-7.21(m,4H),6.98(t,J＝6.8Hz,1H),1.47(s,9H).HRMS(ESI):计算值C22H24N5O4(M+H)+422.1828,实验值422.1823.
4. 3-(5-(甲基氨基甲酰基-2-(苯基氨基)嘧啶-4-氨基)苯基)氨基甲酸叔丁酯的合成
Figure PCTCN2016073726-appb-000026
称取4-((3-((叔丁氧基羰基)氨基)苯基)氨基)-2-(苯基氨基)嘧啶-5-甲酸(1.263g,3mmol)、DIPEA(0.774g,6mmol)于50mL烧瓶，加入10mL无水DMF溶解。另取HATU (1.368g,3.6mmol)，分批加入上述反应液中，室温搅拌1h。加入甲胺盐酸盐(0.396g,6mmol)，室温搅拌过夜。TLC跟踪原料转化，加入冰水，抽滤，水洗，得3-(5-(甲基氨基甲酰基-2-(苯基氨基)嘧啶-4-氨基)苯基)氨基甲酸叔丁酯0.612g，产率47％。1H NMR(400MHz,DMSO-d6)δ11.33(s,1H),9.59(s,1H),9.31(s,1H),8.64(s,1H),8.50(d,J＝4.8Hz,1H),7.68(d,J＝7.8Hz,2H),7.62(s,1H),7.49(br,1H),7.23(t,J＝7.8Hz,2H),7.19(d,J＝8.0Hz,1H),7.15(d,J＝8.0Hz,1H),6.96(t,J＝7.2Hz,1H),2.79(d,J＝4.4Hz,3H),1.47(s,9H).LC-MS:m/z:435.2(M+H)+.
5.(3-(3-甲基-2,4-二氧代-7-(苯基氨基)-3,4-二氢嘧啶并[4,5-d]嘧啶-1(2H)-基)苯基)氨基甲酸叔丁酯
Figure PCTCN2016073726-appb-000027
称取3-(5-(甲基氨基甲酰基-2-(苯基氨基)嘧啶-4-氨基)苯基)氨基甲酸叔丁酯(0.434g,1mmol)、K2CO3(0.276g,2mmol)于25mL烧瓶，加入5mL无水四氢呋喃溶解，升温回流过夜。TLC跟踪原料转化，冷却至室温，加入冰水，EA萃取，收集有机层，旋转蒸发除去溶剂，粗产品经硅胶柱层析分离(EA/PE＝2:1,v/v)，得193mg，产率42％。1H NMR(400MHz,DMSO-d6)δ9.62(s,1H),8.92(s,1H),7.66(s,1H),7.52(d,J＝8.0Hz,1H),7.45(t,J＝8.0Hz,1H),7.36-7.32(m,2H),7.02(d,J＝8.0Hz,3H),6.90(d,J＝7.6Hz,1H),3.29(s,3H),1.45(s,9H).HRMS(ESI):计算值C24H25N6O4(M+H)+461.1937,实验值461.1939.
6. 1-(3-氨基苯基)-3-甲基-7-(苯基氨基)嘧啶并[4,5-d]嘧啶-2,4(1H，3H)-二酮的合成
Figure PCTCN2016073726-appb-000028
称取(3-(3-甲基-2,4-二氧代-7-(苯基氨基)-3,4-二氢嘧啶并[4,5-d]嘧啶-1(2H)-基)苯基)氨基甲酸叔丁酯(0.193g,0.42mmol)于50mL烧瓶，加入5mL二氯甲烷溶解，慢慢滴加1mL三氟乙酸，室温搅拌过夜。TLC跟踪原料转化，加入饱和NaHCO3溶液中和，二氯甲烷萃取，收集有机层，旋转蒸发除去溶剂，得1-(3-氨基苯基)-3-甲基-7-(苯基氨基)嘧啶并[4,5-d]嘧啶-2,4(1H，3H)-二酮0.136g，产率90％，产物未经纯化直接用于下步反应。
7.N-(3-(3-甲基-2,4-二氧代-7-(苯基氨基)-3,4-二氢嘧啶并[4,5-d]嘧啶-1(2H)-基)苯基) 丙烯酰胺的合成(化合物001)
Figure PCTCN2016073726-appb-000029
称取1-(3-氨基苯基)-3-甲基-7-(苯基氨基)嘧啶并[4,5-d]嘧啶-2,4(1H，3H)-二酮(0.136g,0.38mmol)、DIPEA(0.097g,0.76mmol)与25mL烧瓶，加入3mL二氯甲烷溶解，冰浴下搅拌15分钟。另取丙烯酰氯(0.041g,0.46mmol)溶于1mL二氯甲烷，滴加到上述反应液中，室温搅拌过夜。TLC跟踪原料转化，旋干，粗品经硅胶柱层析分离(EA/PE＝1.5:1,v/v)，得N-(3-(3-甲基-2,4-二氧代-7-(苯基氨基)-3,4-二氢嘧啶并[4,5-d]嘧啶-1(2H)-基)苯基)丙烯酰胺83mg，产率53％。1H NMR(400MHz,DMSO-d6)δ10.38(s,1H),8.93(s,1H),7.82(d,J＝3.2Hz,1H),7.80(s,1H),7.53(t,J＝8.0Hz,1H),7.33-7.29(m,2H),7.15(d,J＝7.8Hz,1H),7.02-6.96(m,2H),6.89(t,J＝6.0Hz,1H),6.44(dd,J＝17.2Hz,J＝10.4Hz,1H),6.26(dd,J＝17.2Hz,J＝1.6Hz,1H),5.76(dd,J＝10.4Hz,J＝2.0Hz,1H),3.30(s,3H).HRMS(ESI):计算值C22H19N6O3(M+H)+415.1519,实验值415.1512.
以下化合物(化合物002-010)均按照上述步骤a-g的方法合成得到：
N-(3-(7-((4-甲氧基苯基)氨基)-3-甲基-2,4-二氧代-3,4-二氢嘧啶并[4,5-d]嘧啶-1(2H))苯基)丙烯酰胺(化合物002)
Figure PCTCN2016073726-appb-000030
1H NMR(400MHz,DMSO-d6)δ10.37(s,1H),10.23(s,1H),8.88(s,1H),7.82(d,J＝8.0Hz,1H),7.79(s,1H),7.53(t,J＝8.0Hz,1H),7.22(d,J＝7.6Hz,2H),7.12(d,J＝8.0Hz,1H),6.56(d,J＝7.6Hz,2H),6.44(dd,J＝16.8Hz,J＝10.0Hz,1H),6.24(dd,J＝16.8Hz,J＝1.6Hz,1H),5.76(dd,J＝10.0Hz,J＝1.6Hz,1H),3.65(s,3H),3.29(s,3H).HRMS(ESI)计算值C23H21N6O4[M+H]+445.1624,实验值445.1627。
N-(3-(7-((2-甲氧基苯基)氨基)-3-甲基-2,4-二氧代-3,4-二氢嘧啶并[4,5-d]嘧啶-1(2H))苯基)丙烯酰胺(化合物003)
Figure PCTCN2016073726-appb-000031
1H NMR(400MHz,DMSO-d6)δ10.34(s,1H),8.89(s,1H),8.68(s,1H),7.80(s,1H),7.76(d,J＝8.0Hz,1H),7.50(t,J＝8.0Hz,1H),7.41(d,J＝8.0Hz,1H),7.12(d,J＝7.6Hz,1H),6.95(d,J＝7.6Hz,2H),6.44(dd,J＝16.8Hz,J＝10.0Hz,1H),6.25(dd,J＝17.2Hz,J＝2.0Hz,1H),5.76(dd,J＝10.4Hz,J＝2.0Hz,1H),3.78(s,3H),3.29(s,3H).HRMS(ESI)计算值C23H21N6O4[M+H]+445.1624,实验值445.1631。
N-(3-(7-((2-甲氧基-4-吗啉代苯基)氨基)-3-甲基-2,4-二氧代-3,4-二氢嘧啶并[4,5-d]嘧啶-1(2H))苯基)丙烯酰胺(化合物004)
Figure PCTCN2016073726-appb-000032
1H NMR(400MHz,DMSO-d6)δ10.36(s,1H),8.80(s,1H),8.44(s,1H),8.03(s,1H),7.85(d,J＝8.0Hz,1H),7.69(t,J＝2.0Hz,1H),7.52(t,J＝8.4Hz,1H),7.31(d,J＝8.8Hz,1H),7.09(d,J＝7.6Hz,1H),6.57(d,J＝2.0Hz,1H),6.45(dd,J＝16.8Hz,J＝10.0Hz,1H),6.26(dd,J＝17.2Hz,J＝2.0Hz,1H),5.77(dd,J＝10.4Hz,J＝2.0Hz,1H),3.77(s,3H),3.58-3.54(m,4H),3.06-2.99(m,4H),2.05(s,3H).HRMS(ESI)计算值C27H28N7O5[M+H]+528.1995,实验值528.1993。
N-(3-(7-((2-甲氧基-4-硫代吗啉代苯基)氨基)-3-甲基-2,4-二氧代-3,4-二氢嘧啶并[4,5-d]嘧啶-1(2H))苯基)丙烯酰胺(化合物005)
Figure PCTCN2016073726-appb-000033
1H NMR(400MHz,DMSO-d6)δ10.35(s,1H),8.84(s,1H),8.60(s,1H),8.85(s,1H),7.70(s,1H),7.48(t,J＝8.0Hz,1H),7.17(d,J＝8.4Hz,1H),7.09(d,J＝7.6Hz,1H),6.44(dd,J＝17.2Hz,J＝10.0Hz,1H),6.27(dd,J＝16.8Hz,J＝2.0Hz,1H),5.97(s,1H),5.77(dd,J＝10.0Hz,J＝1.6Hz,1H),3.75(s,3H),3.42-3.39(m,4H),3.28(s,3H),2.66-2.63(m,4H).HRMS(ESI)计算值C27H28N7O4S[M+H]+546.1923,实验值546.1924。
N-(3-(7-((4-(4-乙酰基-3-)-2-甲氧基苯基)氨基)-3-甲基-2,4-二氧代-3,4-二氢嘧啶并[4,5-d]嘧啶-1(2H))苯基)丙烯酰胺(化合物006)
Figure PCTCN2016073726-appb-000034
1H NMR(400MHz,DMSO-d6)δ10.34(s,1H),8.83(s,1H),8.59(s,1H),7.86(s,1H),7.69(s,1H),7.48(t,J＝8.4Hz,1H),7.17(d,J＝8.8Hz,1H),7.09(d,J＝8.0Hz,1H),6.55(s,1H),6.44(dd,J＝17.2Hz,J＝10.4Hz,1H),6.26(dd,J＝17.2Hz,J＝1.6Hz,1H),5.99(s,1H),5.76(dd,J＝10.0Hz,J＝1.2Hz,1H),3.76(s,3H),3.58-3.54(m,4H),3.28(s,3H),3.05-2.99(m,4H),2.05(s,3H).HRMS(ESI)计算值C29H31N8O5[M+H]+571.2417,实验值571.2417。
N-(3-(7-((4-(4-(二甲氨基)哌啶)-2-甲氧基苯基)氨基)-3-甲基-2,4-二氧代-3,4-二氢嘧啶并[4,5-d]嘧啶-1(2H))苯基)丙烯酰胺(化合物007)
Figure PCTCN2016073726-appb-000035
1H NMR(400MHz,DMSO-d6)δ10.36(s,1H),8.83(s,1H),8.54(s,1H),7.88-7.86(m,1H),7.70(s,1H),7.47(t,J＝8.0Hz,1H),7.16(d,J＝8.4Hz,1H),7.08(d,J＝8.0Hz,1H),6.50-6.43(m,2H),6.26(dd,J＝16.8Hz,J＝1.6Hz,1H),5.98(s,1H),5.76(dd,J＝10.0Hz,J＝1.2Hz,1H),3.75(s,3H),3.59-3.58(m,2H),3.28(s,3H),2.60-2.55(m,2H),2.22(s,6H),1.82-1.79(m,2H),1.47-1.40(m,2H).HRMS(ESI)计算值C30H35N8O4[M+H]+571.2781,实验值571.2780。
N-(3-(7-((4-(4-乙酰哌嗪基)-2-甲氧基苯基)氨基)-3-乙基-2,4-二氧代-3,4-二氢嘧啶并[4,5-d]嘧啶-1(2H))苯基)丙烯酰胺(化合物008)
Figure PCTCN2016073726-appb-000036
1H NMR(400MHz,DMSO-d6)δ10.38(s,1H),8.85(s,1H),8.64(s,1H),7.88(d,J＝4.0Hz,1H),7.69(s,1H),7.49(t,J＝8.0Hz,1H),7.18(d,J＝8.4Hz,1H),7.12(d,J＝7.6Hz,1H),6.55(s,1H),6.46(dd,J＝17.2Hz,J＝10.0Hz,1H),6.27(dd,J＝16.8Hz,J＝1.6Hz,1H),6.00-5.97(m,1H),5.78(dd,J＝10.0Hz,J＝2.0Hz,1H),3.94(q,J＝6.4Hz,2H),3.77(s,3H),3.58-3.54(m,4H),3.05-2.98(m,4H),2.06(s,3H),1.19(t,J＝6.8Hz,3H).HRMS(ESI)计算值C30H33N8O5[M+H]+585.2574,实验值585.2572。
N-(3-(7-((4-(4-乙酰哌嗪基)-2-甲氧基苯基)氨基)-3-异丙基-2,4-二氧代-3,4-二氢嘧啶并[4,5-d]嘧啶-1(2H))苯基)丙烯酰胺(化合物009)
Figure PCTCN2016073726-appb-000037
1H NMR(400MHz,DMSO-d6)δ10.37(s,1H),8.83(s,1H),8.61(s,1H),7.86(d,J＝8.0Hz,1H),7.67(s,1H),7.48(t,J＝8.0Hz,1H),7.17(d,J＝7.6Hz,1H),7.10(d,J＝7.6Hz,1H),6.55(s,1H),6.45(dd,J＝16.8Hz,J＝10.0Hz,1H),6.27(dd,J＝16.8Hz,J＝1.6Hz,1H),6.00-5.97(m,1H),5.78(dd,J＝10.0Hz,J＝2.0Hz,1H),5.15-5.11(m,1H),3.76(s,3H),3.57-3.54(m,4H),3.05-2.97(m,4H),2.05(s,3H),1.44(d,J＝6.4Hz,6H).HRMS(ESI)计算值C31H35N8O5[M+H]+599.2730,实验值599.2731。
N-(3-(7-((4-(4-乙酰基哌嗪-1-基)-2-甲氧基苯基)氨基)-3-苄基-2,4-二氧代-3,4-二氢嘧啶并[4,5-d]嘧啶-1(2H)-基)苯基)丙烯酰胺(化合物010)
Figure PCTCN2016073726-appb-000038
1H NMR(400MHz,DMSO-d6)δ10.36(s,1H),8.87(s,1H),8.69(s,1H),7.87(d,J＝5.6Hz,1H),7.68(s,1H),7.48(t,J＝8.0Hz,1H),7.38(d,J＝6.8Hz,2H),7.33(t,J＝7.2Hz,2H),7.26(t,J＝7.2Hz,1H),7.17(d,J＝8.0Hz,1H),7.12(d,J＝7.8Hz,1H),6.55(s,1H),6.44(dd,J＝16.8Hz,J＝10.0Hz,1H),6.26(dd,J＝17.2Hz,J＝2.0Hz,1H),5.98(s,1H),5.77(dd,J＝10.0Hz,J＝1.6Hz,1H),5.09(s,2H),3.76(s,3H),3.58-3.55(m,4H),3.05-2.97(m,4H),2.05(s,3H).HRMS(ESI)计算值C35H35N8O5[M+H]+647.2730,实验值647.2735。
化合物011的具体合成方法如下：
Figure PCTCN2016073726-appb-000039
试剂和条件：(a)-(e)如前所述；(f)N,N,N'-三甲基乙二胺,K2CO3,DMSO；(n)Zn,NH4Cl,CH3OH；(o)酰氯,Et3N,CH2Cl2,0℃–室温。
7-((4-((2-(二甲基氨基)乙基)(甲基)氨基-2-甲氧基-5-硝基苯基)氨基)-3-甲基-1-苯基嘧啶并[4,5-d]嘧啶-2,4(1H,3H)-二酮的合成
Figure PCTCN2016073726-appb-000040
称取7-((4-氟-2-甲氧基-5-硝基苯基)氨基)-3-甲基-1-苯基嘧啶并[4,5-d]嘧啶-2,4(1H,3H)-二酮(438mg,1mmol)、K2CO3(207mg,1.5mmol)、N,N,N'-三甲基乙二胺(153mg,1.5mmol)于10mL单口烧瓶，加入4mL DMSO溶解，升温至90℃，搅拌4h。TLC跟踪至原料转化，冷却至室温，加入冰水，乙酸乙酯萃取，收集有机相，旋干，粗品经硅胶柱层析分离(DCM/CH3OH＝20:1,v/v)，得7-((4-((2-(二甲基氨基)乙基)(甲基)氨基-2-甲氧基-5-硝基苯基)氨基)-3-甲基-1-苯基嘧啶并[4,5-d]嘧啶-2,4(1H,3H)-二酮358mg，产率69％。1H NMR(400MHz,CDCl3)δ8.97(s,1H),7.88(s,1H),7.63(s,1H),7.46-7.43(m,3H),7.19-7.16(m,2H),6.52(s,1H),3.83(s,3H),3.39(s,3H),3.08(t,J＝6.4Hz,2H),2.71(s,3H),2.41(t,J＝6.8Hz,2H),2.17(s,6H).LC-MS:m/z:521.3(M+H)+.
7-((5-氨基-4-((2-(二甲基氨基)乙基)(甲基)氨基)-2-甲氧基苯基)氨基)-3-甲基-1-苯基 嘧啶并[4,5-d]嘧啶-2,4(1H,3H)-二酮的合成
Figure PCTCN2016073726-appb-000041
称取7-((4-((2-(二甲基氨基)乙基)(甲基)氨基-2-甲氧基-5-硝基苯基)氨基)-3-甲基-1-苯基嘧啶并[4,5-d]嘧啶-2,4(1H,3H)-二酮(312mg,0.6mmol)于50mL单口烧瓶，加入8mL甲醇溶解，滴入1mL饱和氯化铵溶液，加入锌粉(390mg,6mmol)室温搅拌过夜。TLC跟踪至原料转化，过滤掉锌粉，滤液旋干，粗品经硅胶柱层析分离(DCM/CH3OH＝15:1,v/v)，得7-((5-氨基-4-((2-(二甲基氨基)乙基)(甲基)氨基)-2-甲氧基苯基)氨基)-3-甲基-1-苯基嘧啶并[4,5-d]嘧啶-2,4(1H,3H)-二酮180mg，产率61％。1H NMR(400MHz,CDCl3)δ8.94(s,1H),8.11(s,1H),7.60(t,J＝7.6Hz,2H),7.52(t,J＝7.2Hz,1H),7.33(d,J＝7.6Hz,2H),6.89(s,1H),6.51(s,1H),3.70(s,3H),3.40(s,3H),2.81(t,J＝6.4Hz,2H),2.52(s,3H),2.29(t,J＝6.8Hz,2H),2.19(s,6H).LC-MS:m/z:491.3(M+H)+.
N-(2-((2-(二甲基氨基)乙基)(甲基)氨基)-4-甲氧基-5-((6-甲基-5,7-二氧代-8-苯基-5,6,7,8-四氢嘧啶并[4,5-d]嘧啶-2-基)氨基)苯基)丙烯酰胺的合成(化合物011)
Figure PCTCN2016073726-appb-000042
称取7-((5-氨基-4-((2-(二甲基氨基)乙基)(甲基)氨基)-2-甲氧基苯基)氨基)-3-甲基-1-苯基嘧啶并[4,5-d]嘧啶-2,4(1H,3H)-二酮(147mg,0.3mmol)、DIPEA(77mg,0.6mmol)于25mL烧瓶，加入3mL二氯甲烷溶解，冰浴下搅拌15分钟。另取丙烯酰氯(33mg,0.36mmol)溶于1mL二氯甲烷，滴加到上述反应液中，室温搅拌过夜。TLC跟踪原料转化，旋干，粗品经硅胶柱层析分离(DCM/CH3OH＝15:1,v/v)，得N-(2-((2-(二甲基氨基)乙基)(甲基)氨基)-4-甲氧基-5-((6-甲基-5,7-二氧代-8-苯基-5,6,7,8-四氢嘧啶并[4,5-d]嘧啶-2-基)氨基)苯基)丙烯酰胺80mg，产率49％。1H NMR(400MHz,CDCl3)δ9.36(s,1H),9.08(s,1H),7.88(s,1H),7.50-7.46(m,5H),6.58(dd,J＝17.2Hz,J＝10.0Hz,1H),6.48(dd,J＝ 17.2Hz,J＝1.6Hz,1H),5.83(dd,J＝10.0Hz,J＝2.0Hz,1H),3.83(s,3H),3.48(s,3H),3.23(t,J＝6.0Hz,2H),3.06(t,J＝6.4Hz,2H),2.77(s,6H),2.68(s,3H).HRMS(ESI):计算值C28H33N8O4(M+H)+545.2625,实验值545.2630。
N-(3-(7-((4-(4-(二甲基氨基)哌啶-1-基)-2-甲氧基苯基)氨基)-3-乙基-2,4-二氧代-3,4-二氢嘧啶并[4,5-d]嘧啶-1(2H)-基)苯基)丙烯酰胺(化合物012)
Figure PCTCN2016073726-appb-000043
1H NMR(400MHz,DMSO-d6)δ10.64(s,1H),10.56(s,1H),8.84(s,1H),8.62(s,1H),7.92-7.90(m,1H),7.71(s,1H),7.48(t,J＝8.0Hz,1H),7.17(d,J＝6.8Hz,1H),7.10(d,J＝7.2Hz,1H),6.55-6.49(m,2H),6.28(dd,J＝16.8Hz,J＝1.6Hz,1H),6.00(s,1H),5.78(dd,J＝11.2Hz,J＝1.2Hz,1H),3.94(q,J＝6.4Hz,2H),3.76(s,3H),3.72-3.68(m,2H),2.73(s,6H),2.60(t,J＝8.0Hz,1H),2.63-2.58(m,2H),2.09(d,J＝11.2Hz,2H),1.72-1.68(m,2H),1.18(t,J＝6.4Hz,3H).HRMS(ESI)(m/z):(M+H)+calcd for C31H37N8O4 585.2938,found,585.2928.
N-(3-(7-((4-(4-(二甲基氨基)哌啶-1-基)-2-甲氧基苯基)氨基)-2,4-二氧代-3-丙基-3,4-二氢嘧啶并[4,5-d]嘧啶-1(2H)-基)苯基)丙烯酰胺(化合物013)
Figure PCTCN2016073726-appb-000044
1H NMR(400MHz,DMSO-d6)δ10.54(s,1H),8.84(s,1H),8.63(s,1H),7.92(s,1H),7.69(s,1H),7.49(t,J＝8.0Hz,1H),7.19(d,J＝6.8Hz,1H),7.10(d,J＝7.8Hz,1H),6.54-6.48(m,2H),6.28(dd,J＝16.8Hz,J＝1.2Hz,1H),6.00(s,1H),5.78(dd,J＝10.4Hz,J＝1.6Hz,1H),3.86(t,J＝6.8Hz,2H),3.76(s,3H),3.72-3.69(m,2H),3.26-3.21(m,1H),2.72(s,6H),2.62-2.57(m,2H),2.07(d,J＝11.2Hz,2H),1.70-1.67 (m,2H),1.65-1.60(m,2H),0.90(t,J＝7.2Hz,3H).HRMS(ESI)(m/z):(M+H)+calcd for C32H39N8O4 599.3094,found,599.3099.
N-(3-(7-((4-(4-(二甲基氨基)哌啶-1-基)-2-甲氧基苯基)氨基)-3-异丙基-2,4-二氧代-3,4-二氢嘧啶并[4,5-d]嘧啶-1(2H)-基)苯基)丙烯酰胺(化合物014)
Figure PCTCN2016073726-appb-000045
1H NMR(400MHz,DMSO-d6)δ10.55(s,1H),8.83(s,1H),8.60(s,1H),7.91(s,1H),7.69(s,1H),7.48(t,J＝8.0Hz,1H),7.19(d,J＝5.6Hz,1H),7.10(d,J＝7.6Hz,1H),6.55-6.48(m,2H),6.28(dd,J＝17.2Hz,J＝1.6Hz,1H),6.00(s,1H),5.78(dd,J＝10.0Hz,J＝1.6Hz,1H),5.17-5.10(m,1H),3.76(s,3H),3.72-3.68(m,2H),3.26-3.20(m,1H),2.72(s,6H),2.63-2.59(m,2H),2.07(d,J＝10.8Hz,2H),1.70-1.67(m,2H),1.44(d,J＝6.8Hz,6H).HRMS(ESI)(m/z):(M+H)+calcd for C32H39N8O4 599.3094,found,599.3079.
N-(3-(3-苄基-7-((4-(4-(二甲基氨基)哌啶-1-基)-2-甲氧基苯基)氨基)-2,4-二氧代-3,4-二氢嘧啶并[4,5-d]嘧啶-1(2H)-基)苯基)丙烯酰胺(化合物015)
Figure PCTCN2016073726-appb-000046
1H NMR(400MHz,DMSO-d6)δ10.54(s,1H),8.87(s,1H),8.69(s,1H),7.91(s,1H),7.69(s,1H),7.48(t,J＝8.0Hz,1H),7.38(d,J＝7.2Hz,2H),7.33(t,J＝7.2Hz,2H),7.26(t,J＝7.2Hz,1H),7.19(d,J＝8.0Hz,1H),7.11(d,J＝6.8Hz,1H),6.54-6.47(m,2H),6.27(dd,J＝16.8Hz,J＝1.6Hz,1H),6.01-5.99(m,1H),5.77(dd,J＝10.0Hz,J＝1.6Hz,1H),5.10(s,2H),3.76(s,3H),3.72-3.69(m,2H),3.27-3.21(m,1H),2.73(s,6H),2.62-2.57(m,2H),2.08(d,J＝11.2Hz,2H),1.71-1.68(m,2H).HRMS(ESI)(m/z): (M+H)+calcd for C36H39N8O4 647.3094,found,647.3088.
N-(3-(7-((4-(4-(二甲基氨基)哌啶-1-基)-2-甲氧基苯基)氨基)-2,4-二氧代-3-苯乙基-3,4-二氢嘧啶并[4,5-d]嘧啶-1(2H)-基)苯基)丙烯酰胺(化合物016)
Figure PCTCN2016073726-appb-000047
1H NMR(400MHz,DMSO-d6)δ10.58(s,1H),8.85(s,1H),8.67(s,1H),7.91(s,1H),7.72(s,1H),7.49(t,J＝8.0Hz,1H),7.32(t,J＝7.6Hz,2H),7.26-7.23(m,3H),7.19(d,J＝12.8Hz,1H),7.07(d,J＝6.8Hz,1H),6.56-6.49(m,2H),6.28(dd,J＝17.2Hz,J＝1.6Hz,1H),6.01-5.99(m,1H),5.78(dd,J＝10.4Hz,J＝1.6Hz,1H),4.10-4.08(m,2H),3.77(s,3H),3.72-3.69(m,2H),3.24-3.19(m,1H),2.90(t,J＝7.6Hz,2H),2.71(s,6H),2.62-2.57(m,2H),2.07(d,J＝11.2Hz,2H),1.70-1.68(m,2H).HRMS(ESI)(m/z):(M+H)+calcd for C37H41N8O4 661.3251,found,661.3251.
N-(3-(7-((4-(4-(二甲基氨基)哌啶-1-基)-2-甲氧基苯基)氨基)-2,4-二氧代-3-(3-苯基丙基)-3,4-二氢嘧啶并[4,5-d]嘧啶-1(2H)-基)苯基)丙烯酰胺(化合物017)
Figure PCTCN2016073726-appb-000048
1H NMR(400MHz,DMSO-d6)δ10.72(s,1H),8.81(s,1H),8.60(s,1H),7.92(s,1H),7.78(s,1H),7.48(t,J＝8.0Hz,1H),7.28-7.19(m,5H),7.14(t,J＝7.2Hz,1H),7.07(d,J＝7.2Hz,1H),6.61-6.52(m,2H),6.29(dd,J＝17.2Hz,J＝1.6Hz,1H),6.02(s,1H),5.78(dd,J＝10.0Hz,J＝1.6Hz,1H),3.94(t,J＝7.2Hz,2H),3.76(s,3H),3.22-3.17(m,1H),2.69(s,6H),2.68-2.63(m,4H),2.08(d,J＝10.4Hz,2H),1.94(t,J＝6.8Hz,2H).HRMS(ESI)(m/z):(M+H)+calcd for C38H43N8O4 675.3407,found,675.3403.
N-(3-(3-异丙基-7-((2-甲氧基-4-(4-甲基哌嗪-1-基)苯基)氨基)-2,4-二氧代-3,4-二氢嘧啶并[4,5-d]嘧啶-1(2H)-基)苯基)丙烯酰胺(化合物018)
Figure PCTCN2016073726-appb-000049
1H NMR(400MHz,DMSO-d6)δ10.64(s,1H),8.83(s,1H),8.63(s,1H),7.85(d,J＝7.2Hz,1H),7.73(s,1H),7.47(t,J＝8.0Hz,1H),7.20(d,J＝8.4Hz,1H),7.09(d,J＝7.6Hz,1H),6.56-6.51(m,2H),6.27(dd,J＝17.2Hz,J＝1.6Hz,1H),6.03-6.01(m,1H),5.77(dd,J＝10.4Hz,J＝1.2Hz,1H),5.17-5.10(m,1H),3.76(s,3H),3.29(t,J＝4.0Hz,4H),3.20(t,J＝4.0Hz,4H),2.75(s,3H),1.44(d,J＝6.4Hz,6H).HRMS(ESI)(m/z):(M+H)+calcd for C30H35N8O4 571.2781,found,571.2775.
N-(3-(7-((4-((2-(二甲基氨基)乙基)甲基)氨基)-2-甲氧基苯基)氨基)-3-异丙基-2,4-二氧代-3,4-二氢嘧啶并[4,5-d]嘧啶-1(2H)-基)苯基)丙烯酰胺(化合物019)
Figure PCTCN2016073726-appb-000050
1H NMR(400MHz,CDCl3)δ8.94(s,1H),8.45(s,1H),7.95(s,1H),7.83(s,1H),7.68(d,J＝8.0Hz,1H),7.46(t,J＝8.0Hz,1H),7.35(d,J＝8.8Hz,1H),7.04(d,J＝7.6Hz,1H),6.38(dd,J＝16.8Hz,J＝1.6Hz,1H),6.27-6.17(m,2H),5.83(dd,J＝9.6Hz,J＝1.6Hz,1H),5.69(d,J＝10.4Hz,1H),5.36-5.29(m,1H),3.81(s,3H),3.39(t,J＝7.6Hz,2H),2.88(s,3H),2.45(t,J＝7.6Hz,2H),2.32(s,6H),1.55(d,J＝6.8Hz,6H).HRMS(ESI)(m/z):(M+H)+calcd for C30H37N8O4 573.2938,found,573.2932.
N-(3-(7-((4-(2-(二甲基氨基)乙氧基)-2-甲氧基苯基)氨基)-3-异丙基-2,4-二氧代-3,4-二氢嘧啶并[4,5-d]嘧啶-1(2H)-基)苯基)丙烯酰胺(化合物020)
Figure PCTCN2016073726-appb-000051
1H NMR(400MHz,DMSO-d6)δ10.39(s,1H),8.84(s,1H),8.64(s,1H),7.80(d,J＝7.2Hz,1H),7.71(s,1H),7.48(t,J＝8.0Hz,1H),7.22(d,J＝8.0Hz,1H),7.10(d,J＝6.0Hz,1H),6.52-6.42(m,2H),6.29(dd,J＝17.2Hz,J＝10.4Hz,1H),5.99-5.78(m,1H),5.75(dd,J＝10.4Hz,J＝1.6Hz,1H),5.15-5.11(m,1H),3.95(t,J＝4.0Hz,4H),3.75(s,3H),2.61(t,J＝4.0Hz,4H),2.22(s,6H),1.44(d,J＝6.8Hz,6H).HRMS(ESI)(m/z):(M+H)+calcd for C29H34N7O5 560.2621,found,560.2627.
N-(3-(3-异丙基-7-((3-甲氧基-4-(4-甲基哌嗪-1-基)苯基)氨基)-2,4-二氧代-3,4-二氢嘧啶并[4,5-d]嘧啶-1(2H)-基)苯基)丙烯酰胺(化合物021)
Figure PCTCN2016073726-appb-000052
1H NMR(400MHz,DMSO-d6)δ10.51(s,1H),10.18(s,1H),8.88(s,1H),7.89(s,1H),7.72(s,1H),7.50(t,J＝8.0Hz,1H),7.13(d,J＝8.0Hz,1H),6.91(s,1H),6.49(dd,J＝16.8Hz,J＝10.0Hz,1H),6.43-6.41(m,1H),6.27(dd,J＝16.8Hz,J＝1.6Hz,1H),5.77(dd,J＝10.0Hz,J＝1.6Hz,1H),5.18-5.11(m,1H),3.56(s,3H),3.04-3.01(m,8H),2.63(s,3H),1.44(d,J＝6.8Hz,6H).HRMS(ESI)(m/z):(M+H)+calcd for C30H35N8O4 571.2781,found,571.2773.
N-(3-(3-异丙基-7-((3-甲基-4-(4-甲基哌嗪-1-基)苯基)氨基)-2,4-二氧代-3,4-二氢嘧啶并[4,5-d]嘧啶-1(2H)-基)苯基)丙烯酰胺(化合物022)
Figure PCTCN2016073726-appb-000053
1H NMR(400MHz,DMSO-d6)δ10.54(s,1H),10.22(s,1H),8.88(s,1H),7.90(d,J＝7.2Hz,1H),7.74(s,1H),7.51(t,J＝8.0Hz,1H),7.18(s,1H),7.13(d,J＝8.0Hz,1H),7.08(d,J＝6.4Hz,1H),6.69(d,J＝7.6Hz,1H),6.50(dd,J＝17.2Hz,J＝10.4Hz,1H),6.26(dd,J＝17.2Hz,J＝1.6Hz,1H),5.76(dd,J＝10.4Hz,J＝1.6Hz,1H),5.18-5.11(m,1H),3.12(t,J＝4.0Hz,4H),2.92(t,J＝4.0Hz,4H),2.70(s,3H),1.97(s,3H),1.44(d,J＝7.2Hz,6H).HRMS(ESI)(m/z):(M+H)+calcd for C30H35N8O3 555.2832,found,555.2831.
N-(3-(3-异丙基-7-((2-甲氧基-4-(4-(4-甲基哌嗪-1-基)哌啶-1-基)苯基)氨基)-2,4-二氧代-3,4-二氢嘧啶并[4,5-d]嘧啶-1(2H)-基)苯基)丙烯酰胺(化合物023)
Figure PCTCN2016073726-appb-000054
1H NMR(400MHz,DMSO-d6)δ10.57(s,1H),8.82(s,1H),8.57(s,1H),7.91(s,1H),7.70(s,1H),7.47(t,J＝8.0Hz,1H),7.18(d,J＝6.8Hz,1H),7.09(d,J＝7.6Hz,1H),6.56-6.49(m,2H),6.27(dd,J＝16.8Hz,J＝1.6Hz,1H),5.99-5.97(m,1H),5.77(dd,J＝10.0Hz,J＝1.6Hz,1H),5.17-5.10(m,1H),3.76(s,3H),3.64-3.61(m,2H),2.96-2.75(m,6H),2.60-2.56(m,6H),1.87-1.85(m,1H),1.54-1.50(m,2H),1.44(d,J＝6.8Hz,6H).HRMS(ESI)(m/z):(M+H)+calcd for C35H44N9O4 654.3516,found,654.3519.
实施例2.生物活性测试
本发明提供的化合物对EGFR激酶活性的体外抑制效果实验如下进行：
体外酶活性分析：野生型及各种突变型(T790M,L858/T790M)EGFR均购自于Invitrogen。为所有的待测试化合物设置了从5.1×10-11mol/L到1.0×10-6mol/L的10个浓度梯度。
不同激酶的浓度由优化实验决定，相应的浓度为：EGFR(PV3872,Invitrogen)0.287μg/μL,EGFR-T790M(PV4803,Invitrogen)0.174μg/μL,EGFR-L858R/T790M(PV4879,Invitrogen)0.055μg/μL。化合物在DMSO中从5.1x10-9M到1x10-4M稀释三倍。4μL化合物溶于96μL水，得到4x的化合物溶液。40μM ATP溶于1.33x激酶缓冲液，激酶/肽混合物包含2x激酶、4μM酪氨酸4肽准备好待用。10μL激酶反应包括2.5μL化合物溶液，5μL激酶/肽混合物，2.5μL ATP溶液。5μL磷酸化肽溶液代替激酶/肽混合物用作100％磷酸化对照。2.5μL 1.33x激酶缓冲液代替ATP溶液用作100％抑制对照，2.5μL 4％DMSO代替化合物溶液用作0％抑制对照。板内溶液充分混合后在室温下培养1.5小时。每孔加入5μL Development Solution后继续在室温下培养1小时，非磷酸化肽在此时间内被裂解。最后，加入5μL终止制剂(Stop Reagent)结束反应。孔板用EnVisionMultilabel Reader(Perkin Elmer)进行测量。实验数据使用GraphPad Prism version4.0进行计算。每次实验均重复3次以上。
细胞增殖及生长抑制分析：H1975(非小细胞肺癌细胞，EGFRL858R/T790M)、A431(非小细胞肺癌细胞，EGFR野生型)，细胞均从ATCC获得。细胞增殖活性采用MTS分析法进行评估。细胞暴露在处理条件下72小时，各细胞系每次实验所使用的细胞数根据吸光度值(490nm处的吸光度值为1.3-2.2)进行调整。为待测试化合物设置了6个浓度梯度(0.1nM-10μM)，每个浓度值至少使用6组平行对照。
H1975、A431细胞在相应的培养基中培养，细胞在复苏后至少传代两次，然后用于实验使用。对数期的细胞受胰蛋白酶作用并在培养基中再悬浮。H1975(每孔1000细胞)、A431(每孔2000细胞)播种于96孔板中，体积100μL；设置6组平行及7列。孔板放于37℃ 5％二氧化碳的培养箱中过夜。将化合物溶于DMSO，配制浓度为每升10μM，随后将化合物浓度逐步稀释得到的化合物浓度分别为每升10μM、1μM、0.1μM、0.01μM、0.001μM、0.0001μM。2μL化合物溶液加到998μL的培养基中，混合物经充分混合。100μL的混合物加入96孔板中。2μL DMSO代替化合物溶液用作0％抑制对照。培养68小时之后，加入20μL MTT(5mg/mL)。4小时候，抛弃上清液并加入150μL DMSO。摇振10分钟之后，孔板用Synergy HT(Bio TeK)(OD490)读取数据。数据使用GraphPad Prism version 4.0进行计算，IC50值通过使用剂量反应曲线的非线性回归模型调整得到。
测试结果如下表1所示。
表1
Figure PCTCN2016073726-appb-000055
Figure PCTCN2016073726-appb-000056
Figure PCTCN2016073726-appb-000057
Figure PCTCN2016073726-appb-000058
Figure PCTCN2016073726-appb-000059
Figure PCTCN2016073726-appb-000060
*：>100表示基本上检测不到对细胞的抑制作用。
讨论：
发明人经过广泛而深入的研究，设计并合成得到了一系列未见文献报道的嘧啶并[4,5-d]嘧啶-2,4(1H,3H)-二酮类化合物，对得到的化合物进行了分子水平和细胞水平的活性测试，得到一批能够选择性抑制EGFR T790M突变的化合物。本发明人进一步发现，本发明的化合物对EGFR突变型癌细胞(H1975)和EGFR野生型癌细胞(A431)的增殖抑制能力差异高于对突变型EGFR和野生型EGFR激酶活性抑制能力差异，从而提示本发明的化合物在体内有更好的差异毒性，有可能成为选择性抑制T790M突变，克服临床耐药的第三代EGFR靶向药物，或者作为经进一步修饰得到活性更佳和/或差异毒性更佳的化合物的基础。
在本发明提及的所有文献都在本申请中引用作为参考，就如同每一篇文献被单独引用作为参考那样。此外应理解，在阅读了本发明的上述讲授内容之后，本领域技术人员可以对本发明作各种改动或修改，这些等价形式同样落于本申请所附权利要求书所限定的范围。

Claims (10)

  1. 通式I所示的化合物或其药学上可接受的盐：
    Figure PCTCN2016073726-appb-100001
    式中，A为苯环、五元或六元杂环、C3-C8环烷基；
    R1各自独立选自氢、卤素、C1-C3烷氧基、C1-C3烷基、C1-C4烷基酰胺基、取代的哌嗪基、取代的高哌嗪基、取代的吗啉基、取代的硫代吗啉基、4-N-甲基哌嗪基、4-N-乙酰基哌嗪基、4-N,N-二甲基哌啶基、取代的哌啶基、-NRaRb，其中，Ra和Rb可独立选自烷基和含氮烷基；
    R2各自独立选自以下基团：
    Figure PCTCN2016073726-appb-100002
    R3选自下组：氢、C1-C10烷基，取代的C1-C10烷基、C2-C6链烯基、C2-C6炔基、任选取代的C3-C8环烷基、任选取代的芳基、任选取代的苄基、任选取代的杂环基、任选取代的芳杂环基；
    B选自下组：
    Figure PCTCN2016073726-appb-100003
    m为0-7的整数。
  2. 如权利要求1所述的化合物或其药学上可接受的盐，其特征在于，所述化合物如通式II所示：
    Figure PCTCN2016073726-appb-100004
    式中，B、R1、R2、R3如权利要求1所限定；
    m为0-5的整数。
  3. 如权利要求2所述的化合物或其药学上可接受的盐，其特征在于，所述化合物如通式III所示：
    Figure PCTCN2016073726-appb-100005
    式中，
    R2选自
    Figure PCTCN2016073726-appb-100006
    R3选自C1-C6烷基，优选甲基或异丙基；或苯基取代的C1-C6烷基，优选苄基；
    R4、R5、R6、R7和R8独立选自下组：
    Figure PCTCN2016073726-appb-100007
    Figure PCTCN2016073726-appb-100008
    和C1-C3烷基。
  4. 如权利要求3所述的化合物或其药学上可接受的盐，其特征在于，R5和R8为H；或者，R5、R7和R8为H。
  5. 选自下组的化合物或其药学上可接受的盐：
    Figure PCTCN2016073726-appb-100009
    Figure PCTCN2016073726-appb-100010
    Figure PCTCN2016073726-appb-100011
  6. 一种药物组合物，所述药物组合物含有权利要求1-5中任一项所述的化合物或其药学上可接受的盐，以及药学上可接受的载体或赋形剂。
  7. 权利要求1-5中任一项所述的化合物在制备治疗或预防EGFR介导的疾病，或抑制EGFR的药物中的用途。
  8. 如权利要求7所述的用途，其特征在于，所述EGFR介导的疾病为癌症。
  9. 如权利要求8所述的用途，其特征在于，所述癌症选自下组：非小细胞肺癌、小细胞肺癌、肺腺癌、肺鳞癌、乳腺癌、前列腺癌、神经胶质细胞瘤、卵巢癌、头颈部鳞癌、宫颈癌、食管癌、肝癌、肾癌、胰腺癌、结肠癌、皮肤癌、白血病、淋巴瘤、胃癌、多发性骨髓癌和实体瘤。
  10. 利用权利要求1-5中任一项所述的化合物治疗或预防EGFR介导的疾病方法。
PCT/CN2016/073726 2015-02-06 2016-02-06 作为egfr抑制剂的嘧啶并嘧啶二酮衍生物及其应用 WO2016124160A1 (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201680008995.3A CN107428763B (zh) 2015-02-06 2016-02-06 作为egfr抑制剂的嘧啶并嘧啶二酮衍生物及其应用

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201510064374.4A CN105985342B (zh) 2015-02-06 2015-02-06 作为egfr抑制剂的嘧啶并嘧啶二酮衍生物及其应用
CN201510064374.4 2015-02-06

Publications (1)

Publication Number Publication Date
WO2016124160A1 true WO2016124160A1 (zh) 2016-08-11

Family

ID=56563485

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2016/073726 WO2016124160A1 (zh) 2015-02-06 2016-02-06 作为egfr抑制剂的嘧啶并嘧啶二酮衍生物及其应用

Country Status (2)

Country Link
CN (2) CN105985342B (zh)
WO (1) WO2016124160A1 (zh)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017144025A1 (zh) * 2016-02-26 2017-08-31 华东理工大学 作为EGFR抑制剂的嘧啶并[4,5-d][1,3]噁嗪-2-酮衍生物及其应用
WO2018192532A1 (zh) * 2017-04-19 2018-10-25 华东理工大学 作为btk抑制剂的杂环化合物及其应用
WO2022116943A1 (zh) * 2020-12-02 2022-06-09 上海瑛派药业有限公司 取代的稠合双环化合物作为激酶抑制剂及其应用
CN115710215A (zh) * 2017-06-21 2023-02-24 肯塔基大学研究基金会 用于治疗癌症的苯乙炔基取代苯和杂环及其应用
WO2023239165A1 (ko) * 2022-06-08 2023-12-14 한국화학연구원 페닐설폰아마이드 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
CN115710215B (zh) * 2017-06-21 2024-06-04 肯塔基大学研究基金会 用于治疗癌症的苯乙炔基取代苯和杂环及其应用

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105985342B (zh) * 2015-02-06 2018-07-24 华东理工大学 作为egfr抑制剂的嘧啶并嘧啶二酮衍生物及其应用
EP4019021A4 (en) * 2019-08-23 2022-11-02 Beijing Tide Pharmaceutical Co., Ltd. INHIBITING AND INDUCING DEGRADATION OF EGFR AND ALK
CN112321814B (zh) * 2020-12-30 2021-03-23 广州初曲科技有限公司 一种吉非替尼艾地苯醌轭合物的制备及用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102816162A (zh) * 2011-06-10 2012-12-12 中国科学院广州生物医药与健康研究院 嘧啶并嘧啶酮类化合物及其药用组合物和应用
WO2015006492A1 (en) * 2013-07-09 2015-01-15 Dana-Farber Cancer Institute, Inc. Kinase inhibitors for the treatment of disease

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2376494A4 (en) * 2008-12-12 2012-07-11 Msd Kk DIHYDROPYRIMIDOPIRYMIDINE DERIVATIVES
CN105985342B (zh) * 2015-02-06 2018-07-24 华东理工大学 作为egfr抑制剂的嘧啶并嘧啶二酮衍生物及其应用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102816162A (zh) * 2011-06-10 2012-12-12 中国科学院广州生物医药与健康研究院 嘧啶并嘧啶酮类化合物及其药用组合物和应用
WO2015006492A1 (en) * 2013-07-09 2015-01-15 Dana-Farber Cancer Institute, Inc. Kinase inhibitors for the treatment of disease

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017144025A1 (zh) * 2016-02-26 2017-08-31 华东理工大学 作为EGFR抑制剂的嘧啶并[4,5-d][1,3]噁嗪-2-酮衍生物及其应用
WO2018192532A1 (zh) * 2017-04-19 2018-10-25 华东理工大学 作为btk抑制剂的杂环化合物及其应用
CN108727382A (zh) * 2017-04-19 2018-11-02 华东理工大学 作为btk抑制剂的杂环化合物及其应用
CN108727382B (zh) * 2017-04-19 2022-07-19 华东理工大学 作为btk抑制剂的杂环化合物及其应用
CN115710215A (zh) * 2017-06-21 2023-02-24 肯塔基大学研究基金会 用于治疗癌症的苯乙炔基取代苯和杂环及其应用
CN115710215B (zh) * 2017-06-21 2024-06-04 肯塔基大学研究基金会 用于治疗癌症的苯乙炔基取代苯和杂环及其应用
WO2022116943A1 (zh) * 2020-12-02 2022-06-09 上海瑛派药业有限公司 取代的稠合双环化合物作为激酶抑制剂及其应用
WO2023239165A1 (ko) * 2022-06-08 2023-12-14 한국화학연구원 페닐설폰아마이드 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물

Also Published As

Publication number Publication date
CN107428763B (zh) 2020-02-21
CN105985342A (zh) 2016-10-05
CN105985342B (zh) 2018-07-24
CN107428763A (zh) 2017-12-01

Similar Documents

Publication Publication Date Title
CN107428763B (zh) 作为egfr抑制剂的嘧啶并嘧啶二酮衍生物及其应用
CN107922417B (zh) 蝶啶酮衍生物作为egfr抑制剂的应用
US9670213B2 (en) Pteridine ketone derivative and applications thereof as EGFR, BLK, and FLT3 inhibitor
KR101839915B1 (ko) 아릴아미노 퓨린 유도체, 그의 제조 방법 및 약학적 용도
CN108727382B (zh) 作为btk抑制剂的杂环化合物及其应用
US20150152088A1 (en) Alkynyl heteroaromatic compound and use thereof
CN103421010A (zh) 作为egfr抑制剂的蝶啶酮衍生物及其应用
WO2017144025A1 (zh) 作为EGFR抑制剂的嘧啶并[4,5-d][1,3]噁嗪-2-酮衍生物及其应用
WO2017101862A1 (zh) 作为egfr抑制剂的5,8-二氢蝶啶-6,7-二酮衍生物及其应用
US11834454B2 (en) Alkynylphenylbenzamide compounds and applications thereof
CN113801118A (zh) 作为rsk抑制剂的蝶啶酮衍生物及其应用
CN113801139A (zh) 作为rsk抑制剂的嘧啶并恶嗪衍生物及其应用
WO2023046114A1 (zh) 蝶啶酮衍生物及其应用
KR20200011990A (ko) 단백질 키나제 저해제로서 유용한 피리도퀴나졸린 유도체
CN113493436B (zh) 胺基取代吡啶衍生物及其制法和药物组合物与用途
CN116354964A (zh) 作为btk抑制剂的7（8h）-喋啶酮衍生物及其应用
WO2024056090A1 (zh) 作为rsk抑制剂的吡咯并嘧啶衍生物及其应用
CN117720531A (zh) 作为rsk抑制剂的吡啶酮并嘧啶衍生物及其应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16746155

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16746155

Country of ref document: EP

Kind code of ref document: A1